

AD_____

Award Number: DAMD17-00-1-0526

TITLE: Accelerated Tumor Cell Death by Angiogenic Modifiers

PRINCIPAL INVESTIGATOR: Leland W.K. Chung, Ph.D.
Chia-Ling Hsieh, Ph.D.
Michael Bradley
Mitchell H. Sokoloff, M.D.

CONTRACTING ORGANIZATION: University of Virginia
Charlottesville, Virginia 22096

REPORT DATE: August 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020719 085

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE August 2001	3. REPORT TYPE AND DATES COVERED Annual (15 Jul 00 - 14 Jul 01)		
4. TITLE AND SUBTITLE Accelerated Tumor Cell Death by Angiogenic Modifiers		5. FUNDING NUMBERS DAMD17-00-1-0526		
6. AUTHOR(S) Leland W.K. Chung, Ph.D. Chia-Ling Hsieh, Ph.D., Michael Bradley, Mitchell H. Sokoloff, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Charlottesville, Virginia 22096 E-Mail: lwchung@emory.edu		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Purpose: Because of the inherent stability of endothelial cells and the importance of this cell type for the proliferation of both localized and disseminated cancers, anti-angiogenic therapy is an attractive target for the investigation and further development of novel therapeutic approaches to cancer metastasis. The purpose of this proposal is to assess molecular mechanisms underlying synergy between squalamine and vascular endothelial growth factors (VEGF).				
14. SUBJECT TERMS Prostate cancer metastasis, angiogenic modifiers, squalamine, vascular endothelial growth factor or VEGF, animal model for prostate cancer, cell death or apoptosis			15. NUMBER OF PAGES 60	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-5
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	6
Appendices.....	6

ABSTRACT

Purpose:

Because of the inherent stability of endothelial cells and the importance of this cell type for the proliferation of both localized and disseminated cancers, anti-angiogenic therapy is an attractive target for the investigation and further development of novel therapeutic approaches to cancer metastasis. The purpose of this proposal is to assess molecular mechanisms underlying synergy between squalamine and vascular endothelial growth factors (VEGF).

Scope:

Angiogenic modifier including VEGF and withdrawal of androgen were used to “injure” the endothelial cells in an effort to enhance squalamine induced tumor shrinkage in animal models of human prostate cancer. The cellular mechanisms underlying tumor cell death in these models will be evaluated.

Major Findings/Progress:

We have completed *in vitro* studies to show synergism between squalamine and VEGF in promoting the death of human prostate cancer cell lines. This synergism appears to be dependent upon the prostate cancer cell background in which LNCaP and C4-2 but not PC-3 and DU-145 cells are highly sensitive to squalamine-VEGF synergy in inducing cell kill. This synergistic action between squalamine and VEGF appears to interfere with the ability of VEGF to stimulate prostate cell attachment to substratum, laminin. Our next goal is to find out the particular downstream pathway that mediates extracellular matrix-intracellular signaling cascade that may be the underlying molecular mechanism that triggers squalamine-VEGF synergism, thus causing human prostate cancer cell death *in vitro*. We have confirmed such synergism *in vivo* in two tumor models: 1) the LNCaP prostate cancer progression model and 2) CWR22 model.

Subject Terms:

Prostate cancer metastasis, angiogenic modifiers, squalamine, vascular endothelial growth factor or VEGF, animal model for prostate cancer, cell death or apoptosis

Introduction:

Cancer growth requires the supply of oxygen and nutrients. Although endothelial cells are responsible for forming new vasculatures for the delivery of oxygen and nutrients and removal of metabolic waste from tumors, it becomes apparent that similar molecular mechanisms may be operating between endothelial and tumor cells.

Body:

The emphasis of the current proposal is three fold. First, we propose to extend our *in vitro* observations of squalamine-VEGF synergism to the *in vivo* mouse model of human prostate cancer using both LNCaP progression and CWR22 models to evaluate if androgen-independent progression of such models may be affected by the administration of squalamine in castrated mice. Second, we propose to evaluate the cellular response of prostate cancer cells to VEGF and squalamine, focusing on the cytoskeletal organization changes in response to squalamine and

VEGF. Possible alterations of cell surface integrin isotypes that may modify integrin-matrix interaction will also be evaluated. Third, we propose to evaluate the downstream intracellular signaling pathways that may be altered by squalamine and/or VEGF. A comparative study will be conducted to evaluate signal transduction in LNCaP progression model and the androgen-independent DU-145 and PC-3 cells. Signal cascade through the VEGF receptor, focal adhesion kinases, FAK, Pyk2, and MAP kinase associated ERK and JNK pathways will be studied in relation to apoptosis of prostate cancer and endothelial cells *in vitro*.

Key Research Accomplishments

- We have observed synergy between VEGF and squalamine *in vitro* in cultured human prostate cancer cell lines. Results of these studies indicated that such synergism may be cell background dependent. For example, LNCaP and C4-2 but not PC-3 or DU-145 cells are highly sensitive to squalamine-VEGF synergy in cell kill *in vitro*. This cell kill appears to be dependent upon VEGF elicited downstream cell signaling, because such synergism can be effectively blocked by the co-presence of VEGF antibody.
- We have evaluated squalamine effect in animal models by the application of another angiogenic modifier, the removal of testicular androgen through castration, which enhances the destruction of endothelial cells. Using both LNCaP and CWR22 models, we have observed the synergism between castration and squalamine, which caused remarkable cell death and tumor shrinkage in these models. We found that such synergism between squalamine and castration only occurred if animals were castrated early, rather than later, upon squalamine application.

These results together imply that at the time of castration, squalamine could have a beneficial effect in causing accelerated tumor cell death in patients with androgen-independent prostate cancer.

Reportable Outcomes:

- A review entitled, "Targeting angiogenic pathways involving tumor-stroma interaction to treat advanced human prostate cancer" has been published by Sokoloff and Chung, *Cancer and Metastasis Review*, 17(4):307-15, 1999.
- A review on molecular mechanism of cotargeting tumor stroma and epithelium has been accepted for publication in J. of Cellular Biochemistry, 2001.

Both of these references are attached with this report.

Conclusions:

- Synergism between squalamine and VEGF was demonstrated in selective prostate cancer cell lines.
- Vascular endothelial cell destruction in castrated animals can be applied as an additional angiogenic modifier to synergize with squalamine-induced tumor cell kill. The "timing" of squalamine application is extremely important, and is highly effective at the time of castration when vascular endothelial cell destruction is maximized, inducing tumor cell death in both LNCaP progression and CWR22 human prostate tumor models.

References:

None

Legends and Figures

Figure 1 – Synergism between squalamine and VEGF was found in selective prostate cancer cell lines *in vitro*. LNCaP and its androgen-independent C4-2 derivative were highly sensitive to this synergistic interaction between VEGF and squalamine, whereas the androgen-independent PC-3 and DU-145 cells were not.

Figure 2 – Squalamine application to animals castrated early was shown to be highly effective in eliminating the growth of LNCaP tumors *in vivo*. Squalamine appeared to be highly effective only when it was applied immediately after castration in animals bearing LNCaP tumor *in vivo*.

Figure 3 – Synergistic interaction between squalamine and castration was also noted in CWR22 model where squalamine application at the time of castration eliminated the growth of CWR22 tumors in animals (panel A). Although the tumor volume appears to decrease upon the treatment by squalamine, the tumor appears to persist because of the secretion of serum PSA in this model (panel B).

These results indicate that it is also possible that squalamine may induce prostate cancer differentiation by promoting PSA synthesis and production in CWR22 models.

Appendices:

- I. Figure 1
- II. Figure 2
- III. Figure 3
- IV. Sokoloff M and Chung LWK. Targeting angiogenic pathways involving tumor-stroma interaction to treat advanced human prostate cancer. *Cancer & Metastasis Reviews*. 17(4):307-15, 1999.
- V. Yeung F and Chung LWKC. Molecular Basis of Co-targeting Prostate Tumor and Stroma. *J. Cell Biochemistry* 2001 (*In Press*)
- VI. Curriculum Vitae

**PROLIFERATION OF PROSTATE TUMOR CELL
LINES IN THE PRESENCE OF SQUALAMINE,
VEGF, AND ANTIBODIES AS MEASURED BY
THYMIDINE INCORPORATION**




Figure 1





Figure 2

Tumor Volumes of Squalemine-Treated and Control CWR22 Tumor




Figure 3A

PSA Changes in Squalmine-Treated and Control CWR22 Tumors




Figure 3B

Molecular Basis of Co-targeting Prostate Tumor and Stroma

Fan Yeung¹ and Leland W. K. Chung²

1. Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908

2. Department of Urology, Emory University School of Medicine, Atlanta, GA 30322

* To whom reprint requests should be addressed.

Abbreviation: Androgen Independent (AI), human osteocalcin (hOC), bone sialoprotein (BSP), osteoprotegerin (OPG), osteonectin (ON), osteopontin (OPN), prostate-specific antigen (PSA), insulin-like growth factor binding protein (IGFBP), transforming growth factor beta (TGF β), parathyroid hormone related protein (PTHrP), insulin-like growth factor (IGF), androgen responsive elements (AREs), androgen responsive element enhancer core (AREc), androgen receptor (AR), electromobility shift assay (EMSA), osteoblast-specific element (OSE), extracellular matrix (ECM), bone morphogenic proteins (BMPs), matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinase (TIMP)

Abstract

Hormone-refractory prostate cancer is one of leading cause of cancer death in Northern American men. The lethal phenotypes of human prostate cancer are characterized by progression to androgen-independence (AI) and a propensity to form osseous metastases. In ~80% of cases, prostate cancer colonizes bone and elicits a characteristic osteoblastic reaction. The bone metastases are initially sensitive to androgen deprivation treatments, but with time the cancer will eventually progress into an AI stage for which there is currently no effective treatment. Once initial hormonal therapy has failed, median survival of prostate cancer patients with bone metastases is less than 1 year (Tu, et al. 2001). Novel therapeutic and preventive strategies are needed to decrease morbidity and mortality of this disease.

In this review, we describe a novel gene therapy strategy in which tissue-specific and tumor-restrictive promoters are employed to drive the expression of therapeutic genes to co-target both the stromal and epithelial compartments in the treatment of prostate cancer bone metastases (Matsubara, et al. 2001). The rationale behind this strategy is based on the evidence that reciprocal stromal-epithelial interactions are important for prostate tumorigenesis and that the osteomimetic properties of prostate cancer cells contribute to prostate cancer progression (Koeneman, et al. 1999).

Regulation of tissue-specific and/or tumor-restrictive promoters, prostate-specific antigens and human osteocalcin, in androgen-independent bone metastatic prostate cancer cells.

Despite the common occurrence of prostate cancer, little is known about the underlying mechanisms responsible for prostate cancer growth, androgen-independent

progression, and acquisition of bone metastatic potential. To gain new insights into the molecular mechanisms of AI progression, our lab focused on defining the transcriptional regulation of human osteocalcin (hOC) and prostate specific antigen (PSA) expressions in AI prostate cancer cell lines. A strategy was outlined to identify the transcription factors involved in regulating the critical regions of the promoters of these genes, and their roles in tumorigenesis (Yeung, et al. 2000; Yeung, et al. 2001). The ultimately goal of our study is to devise strategies for expressing therapeutic genes under the control of tissue-specific promoters to treat prostate cancer bone metastasis effectively.

PSA. Due to its tissue-specific expression pattern, PSA is the most widely used serum marker for the diagnosis and management of prostate cancer. Since the expression of PSA is tightly regulated by androgen, an increase in serum PSA in androgen-depleted patients could indicate the development AI tumors. In addition to being dysregulated during cancer progression, PSA, a serine protease, is believed to contribute significantly at the molecular level to prostate cancer progression and metastasis via its protease activity. For example, the cleavage of IGFBP [Cohen et al., 1992] and TGF β by PSA could increase the bioavailability of the mitogen IGF; and activating the latent form of growth factor TGF β , enhancing matrix turnover, tumor angiogenesis and immune evasiveness. Moreover, the inactivation of PTHrP by PSA [Cramer et al., 1996] could tip the balance toward osteoblastic reactions in prostate cancer bone metastasis.

PSA is one of the most widely studied prostate genes. Numerous groups focused on the androgen regulation of PSA have identified several androgen-responsive elements (AREs) [Cleutjens et al., 1996; Huang et al., 1999] and a tissue-specific enhancer core (AREc) [Cleutjens et al., 1997] in the promoter. To identify transcription factors that

activate PSA promoter independent of androgen, we performed promoter deletion studies and identified two AI regulatory regions (AREc and pN/H), which suggested the involvement of two distinct pathways in androgen-independent regulation of PSA expression in AI C4-2 cells [Yeung et al., 2000]. One pathway clearly involved androgen receptor (AR) because the binding of AR to the AREs within the AREc appears to be prerequisite for the high activity of the AREc and PSA promoter in C4-2 cells. It is plausible that AR is activated through growth factor mediated signaling pathways independent of androgen. Growth factors like IGF-1, EGF and KGF were reported to induce AR-mediated gene transactivation in the absence of androgen [Culig et al., 1994]. These growth factors could signal through the PKA [Nazareth and Weigel, 1996] and/or PKC [Sadar, 1999] cascade in which AR activity is enhanced either by modification of AR itself [Ikonen et al., 1994] or by enhancing the interactions between AR and its coactivators [Yeh et al., 1999]. The fact that AREc is highly tissue specific and contains other cis-elements suggests [Cleutjens et al., 1997] that in addition to AR, other prostate specific co-activators are also involved in the AI regulation of AREc in C4-2 cells. Activated AR is one of the key transcription factors that interact with other prostate-specific transcription factor(s), and together they associate with the AREc and assemble into a highly active AREc enhanceosome complex [Huang et al., 1999] in C4-2 cells. The aberrant activation of AR and/or its co-activators by growth factors could provide growth advantage to cancer cells in an androgen-depleted environment, and this could be one of the important mechanisms that contribute to prostate cancer progression.

The other pathway mediated by pN/H appears to involve an unknown 45-kDa prostate specific transcription factor (p45). Through DNaseI footprinting and linker-

scanning mutagenesis approaches, we showed that p45 binds to a 17 bp site (RI) in the pN/H region and regulates the basal PSA promoter activity. Even though the RI element shares high homology with the SP-1 consensus site, p45 migrates differently from the Sp-1 transcription factors in EMSA, so it does not seem to belong to the Sp-1 transcription factor family. Furthermore, the observed absence of RI-p45 complex in PC3 cells and a higher amount of p45 complex in C4-2 than in LNCaP suggest that the expression of p45 is cell type-specific. Since the addition of androgen could not enhance pN/H activity, p45 does not seem to be regulated by androgen or AR. The fact that C4-2 nuclear extract consistently showed a higher level of RI-p45 complex in EMSA implies that increased association of p45 to RI site is a possible mechanism by which PSA promoter is activated in C4-2 cells in an AR and androgen independent manner [Yeung et al., 2000]. Further efforts to identify p45 may provide additional information on the AI growth and metastasis of prostate cancer cells. For example, P45 may regulate prostate cancer growth by binding to the promoters of the growth-related genes that contain the RI cis-element. The identification of p45 could also be of great clinical significance. Since there is a higher level of p45 in AI prostate cancer cells, new diagnostic approaches based on screening for the level of p45 in tumor cells could provide valuable information for staging the cancer and determining the progression and metastatic potential of the disease.

hOC. Osteocalcin (OC) is one of the major non-collagenous bone matrix proteins expressed in bone. OC expression is transcriptionally regulated by vitamin D and was thought to be limited to cells of the osteoblast lineage. Many regulatory elements have been mapped to the proximal region of the OC promoter. These include OSE1, OSE2

and AP-1/VDRE. OSE1 and OSE2 were first identified in mouse OC promoter and they are associated with osteoblast-specific transcription factors, OSF1 and Runx2, respectively. Vitamin D receptors were shown to bind the VDRE in the proximal promoter, and its activity is tightly regulated by the members of the AP-1 family that bind the contiguous AP-1 site. In proliferating osteoblasts, c-Fos and c-Jun heterodimers were shown to block the binding of VDR and suppress the rat OC promoter activity, while the expression of Fra2 and JunD in the post-proliferated osteoblasts induces rat OC promoter activity by facilitating VDR/RXR binding [Lian et al., 1998].

Human prostate cancer cells with a propensity to metastasize to the skeleton and prostate cancer tissue specimens with increased Gleason scores reveal that prostate cancer cells synthesize, secrete and/or deposit large amounts of non-collagenous bone matrix proteins such as OC, osteopontin (OPN), osteoprotegerin (OPG), osteonectin (ON) and bone sialoprotein (BSP). In a recent study, we demonstrated that OC protein was prevalently expressed in primary prostate cancer (85%), in prostate cancer lymph node (100%) and in bone metastasis specimens (100%) [Chung and Zhau, 2001; Matsubara, et al. 2001]. Since OC was not expressed in normal human prostate gland, the predominant expression of OC and other bone matrix proteins in advanced prostate cancer imply a role in prostate cancer survival and growth in the bone environment. OC secreted by prostate cancer cells can complex with ECM and calcium, serving as a chemoattractant for recruiting osteoblasts and/or osteoclasts, which initiate bone remodeling [Glowacki and Lian, 1987]. This may contribute to the osteotropic characteristics of prostate cancer bone metastasis. The discovery of hOC expression in prostate cancer specimens has opened new windows on biology and therapy of prostate

cancer bone metastasis. In an effort to understand the osteomimetic properties of prostate cancer cells, we used PC3 cells to investigate the regulation of OC expression. PC3 cells are AI, obtained from bone metastatic lesions of a prostate cancer patient. PC3 cells share with mature osteoblasts the unique feature of synthesizing and depositing a large amount of OC. In our study, we demonstrated three groups of transcription factors, Runx2, JunD/Fra-2 and Sp-1, responsible for the high hOC promoter activity in PC3 cells by binding to the OSE2, AP-1/VDRE and OSE1 elements, respectively. Furthermore, the functional hierarchy of OSE1, OSE2 and AP-1/VDRE was established in the regulation of hOC promoter activity (OSE1>AP-1/VDRE>OSE2) in PC3 cells. We also generated an artificial hOC promoter consisting of dimers of the three elements with significantly higher activity than the wild type promoter. Among the three groups of transcription factors, the expression levels of Runx2 and Fra-2 are higher in the OC-positive PC3 cells and osteoblasts, compared to the OC-negative LNCaP cells. Interestingly, unlike the mouse OC promoter, the OSE1 site in hOC promoter is regulated by the members of Sp-1 family instead the osteoblast specific factor, Osf1 [Yeung, et al. 2001]. Therefore, by expressing the osteoblast-specific transcription factor Runx2 and differentially up-regulating the prominent Ap-1 factor, Fra2, in mature osteoblasts, PC3 cells have acquired the phenotypes of osteoblasts. The interplay and coordination among these transcription factors provides the molecular basis for AI prostate cancer cells behaving like mature osteoblasts. The balance and activity of these transcription factors is significant in conferring the osteolytic/osteoblastic phenotype of prostate cancer cells frequently observed in metastatic skeletal lesions.

Osteoblast-specific transcription factors and prostate cancer bone metastasis

Besides OC, the expression of other bone matrix proteins such as OPG, OPN, BSP was also found in bone met prostate cancer cells. It appears that a switch of gene transcription occurs in prostate cancer bone metastasis that allows the cancer cells to acquire an osteoblast phenotype and presumably leads to their colonization in the skeleton. The roles of these bone matrix proteins are unclear, but based on their functions in bone development and remodeling, one can postulate that OPN expression in prostate cancer cells could facilitate their adhesion and migration [Denhardt et al., 2001] to the bone matrix and participate in subsequent bone "pitting" and steps involved in osteoid mineralization. Since BSP has been shown to be crucial for the expression of osteoblastic phenotypes in cultured bone marrow cells [Mizuno et al., 2000], overexpression of BSP by metastatic prostate cancer cells could enhance their attachment to osteoblasts and osteoclasts and stimulate osteoblast differentiation. The expression of OPG in prostate cancer cells may lead to the overall repression of osteoclast activity and a shift of bone remodeling toward osteoblast activity in bone metastasis [Simonet et al., 1997]. Therefore, the osteomimetic properties of prostate cancer cells in theory could allow them to invade, adhere, survive and grow better in the bone microenvironment [Koeneman et al., 1999]. Recent study using the osteotropic prostate cancer cells (C4-2B) demonstrated that in addition to having an osteoblastic phenotype, C4-2B cells could produce hydroxyapatite mineral in vitro; and stimulate osteoblasts to initiate mineralization in the bone [Lin et al., 2001]. The increased expression of bone matrix proteins by prostate cancer cells in skeletal metastatic sites may underlie the predilection

of prostate cancer for bone and explain the mineral formation found in osteoblastic lesions.

Even though tumor metastases in patients with prostate cancer are predominantly osteoblastic, evidence from osteoblastic metastasis animal model indicates that an initial phase of bone resorption precedes new bone formation [Yi et al., 2000]. The importance of osteoclast activity in osteoblastic metastasis was further supported by recent findings that bisphosphonates (an inhibitor of osteoclast activity) could effectively alleviate bone pain in patients with metastatic prostate cancer [Adami, 1997]. Since bone is an abundant source of growth factors such as TGF β , bFGF, IGFs, PDGFs, and BMPs, osteoclastic bone resorption could release and/or activate growth factors from the bone matrix, which could serve as paracrine mediators to stimulate tumor growth [Nakase et al., 1994]. Conceivably, prostate cancer cells could modify the bone microenvironment in a reciprocal manner by secreting soluble factors to promote osteoclasts activity, which in turn makes the bone stroma conducive for the growth and survival of prostate cancer cells. Therefore, the reciprocal interactions between prostate cancer cells and their supporting stroma are essential in promoting cancer progression, invasion and metastasis.

Fra2 is one of the transcription factors that may be involved in bone metastasis. We showed that a higher level of Fra2 was found in AI, bone metastatic prostate cancer cells compared to non-tumorigenic LNCaP prostate cancer cells. It is not clear how Fra2 is upregulated in prostate cancer cells. However, growth factor like TGF β was known to increase the expression and activity of AP-1 factors. The binding of TGF β to its cell surface receptor could trigger a cascade of signaling pathways, including the MAPK pathways. MAPK pathways were indicated to regulate both the amounts and

transactivating activity of the AP-1 factors in a stimulus-specific manner. As an oncoprotein, high level of Fra2 could contribute in numerous ways to increase proliferation, invasion and metastasis of cancer cells during disease progression. For example, over expression of Fra2 reportedly represses the tissue inhibitor of metalloproteinases (TIMP1) promoter activity by forming heterodimers with JunD, which are less active than JunD homodimers [Smart et al., 2001]. The repression of TIMP1 could allow the accumulation of MMPs and lead to increased invasiveness of the tumor. Furthermore, avian primary cells transformed by Jun/Fra2 showed increased anchorage independent growth by their ability to form colonies in soft agar [van Dam et al., 1998]. Therefore, these results are consistent with the notion that enhanced level of Jun/Fra2 confers cell motility and invasiveness.

Runx2 is an osteoblast-specific factor highly expressed in the bone metastatic prostate cancer cells. The expression of this osteoblast-specific factor is believed not only to impart the osteomimetic characteristics of prostate cancer cells, but it also has a significant role in carcinogenesis. BMPs and TGF β are two of the growth factors shown to activate the transcription of Runx2 in bone cells [Bae et al., 2001]. As a member of the TGF β family, BMPs are known to bind receptors and to induce a cascade of events leading to phosphorylation of Smad proteins. Upon phosphorylation, Smad translocate into the nucleus to interact with numerous transcription factors, which then regulate gene expression. Smad5 is believed to be responsible for activating the Runx2 gene transcription [Bae et al., 2001]. Other local factors such as hedgehogs [Yamaguchi et al., 2000] and IGF-1 [Yeh et al., 1997] were shown to synergistically enhance BMPs actions. For example, recombinant Shh and conditioned media collected from Shh-or Ihh-

overexpressing chicken embryonic fibroblasts can increase BMP2, which induces the downstream OC mRNA level [Kinto et al., 1997]. Therefore, hedgehog-signaling pathway may act cooperatively with the BMP signaling pathway in regulating the transcription of Runx2.

Some of the early gene targets of BMP signaling pathway include the N- and E-cadherins. Recombinant human BMP-2 (rhBMP2) rapidly and transiently increases N- and E-cadherin mRNA and protein levels in human osteoblasts. In addition, the N- and E-cadherin antibodies have inhibitory effects on both the basal and induced Runx2 mRNA levels, and abolish the rhBMP2-induced OC mRNA levels [Hay et al., 2000]. The importance of cell-matrix interaction in the regulation of Runx2 expression is further demonstrated by the fact that α 2-integrin-collagen interaction is required for activation of Runx2 and induction of osteoblast-specific gene expression. Induction of matrix synthesis is accompanied by a dramatic increased in the binding of Runx2 to OSE2, suggesting that ECM synthesis up-regulates and/or activates Runx2. Furthermore, blocking of integrin-type I collagen binding prevents activation of the OC promoter by ascorbic acid and suppresses binding of Runx2 to OSE2 site [Xiao et al., 1998]. It is not clear how ECM activates Runx2; it is possible that a post-translational pathway or accessory factor(s) are involved in the regulation. Like the AP-1 factors, the MAPK pathway also regulates Runx2. An activated recombinant MAPK was shown to phosphorylate a Runx2 fusion protein in vitro [Xiao et al., 2000]. Therefore, the phosphorylation of Runx2 through the MAPK pathway is essential for responsiveness of osteoblasts to ECM signals and contributes for osteoblast-specific gene expression

Evidence from tooth development study indicated that Runx2 regulates key epithelial-mesenchymal interactions that control advancing morphogenesis and differentiation of the epithelium. Runx2 expression in the mesenchyme is intimately associated with epithelial-mesenchymal interactions during tooth development and is affected by epithelial signals. Runx2 expression in the mesenchyme is controlled by signals emanating from the epithelium. In turn Runx2 regulates the expression of mesenchymal molecules that act reciprocally on epithelium to control the differentiation of the enamel organ [D'Souza et al., 1999]. It is plausible that the growth factors release from the bone matrix upregulate the expression of Runx2 in prostate cancer cells, as a result triggering a "ping-pong" mechanism (Fig 1) in which the high level of Runx2 allows expression of gene products in the cancer cells that could modify the surrounding stroma and eventually lead to enhance tumor growth.

Potential use of tissue-specific and tumor-restrictive promoters in co-targeting stromal-epithelial interactions in prostate cancer.

Due to the poor response rate of previously treated patients with relapsed prostate cancer to conventional radiotherapy, surgery, or chemotherapy, our laboratory has examined some of the unique biological characteristics associated with prostate cancer and its relationship with prostate or bone stromal cells in the effort to formulate novel targeting strategies. Traditional therapy for prostate cancer has targeted only the malignant epithelial cell. Because of the osteomimetic properties of prostate tumor epithelial cells in bone, we proposed a novel co-targeting strategy incorporating an adenoviral gene therapy approach to the treatment of both localized and metastatic prostate cancers. This approach involves the use of bone matrix protein promoters, such

as OC to drive the expression of therapeutic genes co-targeting tumor epithelium and its supporting stroma to maximize tumor cell-kill.

Gene therapy is a newly developed technology based on understanding the genetic and molecular defect of disease. In dealing with cancer, toxic gene therapy is most commonly employed clinically. This kind of therapy involves suicide gene/prodrug systems, in which a suicide gene is delivered to cancer cells to activate a non-toxic prodrug in cells and thus selectively kill the tumor cells while sparing surrounding normal cells from tissue damage.

The concept of delivery and expression of therapeutic genes to tumor cells through the use of tissue-specific promoters has been well recognized. This approach decreases the adverse effects of the therapeutic genes on normal cells and increases the specificity and efficiency of gene transfer to tumor cells. Attractive approaches for the treatment of bone metastasis could be developed through our understanding of the molecular mechanism underlying the acquisition of osteomimetic properties by prostate cancer cells. The discovery of common bone matrix proteins synthesized by both prostate cancer cells and osteoblast cells, raise the possibility of employing the promoters of these proteins to drive the expression of therapeutic genes in both prostate cancer and bone stromal compartments for therapeutic gains. In this context, our laboratory has developed an OC-based toxic gene therapies for the treatment of prostate cancer metastasis. We envision the use of OC promoter to drive the expression of therapeutic genes in proliferative cellular compartments to eradicate the growth of both prostate cancer cells and their supporting stroma. This approach could achieve a higher degree of efficacy than the conventional approaches of blocking bone proliferation by

bisphosphonate or halting the growth of prostate cancer cells with non-selective chemotherapeutic agents or radiation. The effectiveness of this form of gene therapy can be explained by the uniqueness of the OC promoter, which presumably drives the expression of toxic genes in at least three cellular compartments: tumor epithelium, bone stroma, and vascular endothelial pericytes (Chung and Zhau, 2001). The rationale for co-targeting bone stroma and epithelium was supported by our preliminary data showing that the growth of prostate cancer cells was enhanced when they were co-cultured with bone stroma cells. The destruction of bone stromal cells alone was sufficient for killing the co-cultured prostate cancer cells. Furthermore, a recent study by Tu et al [Tu et al., 2001] demonstrated that bone targeting with chemoinduction plus Strontium 89 (Sr89) significantly improved patient survival in comparison to Sr89 or chemoinduction alone. The improved survival of patients subjected to co-targeting of bone stroma and epithelium by chemoinduction and Sr89 dramatizes the advantages of co-targeting, and supports our strategy of co-targeting tumor epithelium and bone stroma by gene therapy, which could eventually result in improved survival of patients with metastatic bone disease.

Summary

The study of tissue-specific promoters such as PSA and hOC in AI prostate cancer cells has led to the identification of some of the transcription factors (AR, p45, Runx2, and Fra2) that are dysregulated during cancer progression. Although the roles of these transcription factors in tumorigenesis are unclear, it is feasible to use approaches like ribozyme and antisense to block the expression of these transcription factors and determine their respective effects on tumor growth and invasion. Once the functions are

established, we believe effective strategy employing tissue-specific and tumor-specific promoters to control gene expression in selective cell types could be designed to target these transcription factors for cancer gene therapy.

In the past few years, our laboratory has successfully developed a human prostate cancer skeletal metastasis model for the study of the biology and therapeutic targeting stromal-epithelial interactions. We believe the inter- and intra-cellular communication loops between prostate epithelium and its supporting stroma provide additional attractive therapeutic targets for prostate cancer treatment. Results from preliminary animal experiments support the concept that maximum prostate tumor destruction may be achieved by targeting both tumors and their supporting stroma compartments. The development of bone matrix protein promoters, such as OC, driving gene expression in both prostate epithelial and stromal compartments has allowed future explorations into prostate cancer/stroma interactions and signal cascades involving growth factor/growth factor receptor and cell-matrix interactions. Since bone matrix proteins have been implicated in prostate cancer progression, OC promoter could be valuable for delivering genes into both epithelium and stroma compartments to block the expression/secretion of critical factors that affect the growth and survival of cancer cells in vivo. Refining our understanding of the regulation of PSA and bone matrix proteins in prostate cancer cells at the molecular level could facilitate the future development of new molecular targets for the prevention and treatment of not only prostate cancer skeletal metastasis but also localized and invasive prostate cancers.

Acknowledgment: We are grateful to Mr. Gary Mawyer for excellent editorial assistance, Andy Law for advice and discussions, and Dr. Shigeji Matsubara for the

design of Figure 1. Financial support from CA-85555, NASA-NCC8-171, DoD-DAMD17-00-1-0526, CaP CURE Foundation, Kluge Foundation and DirectGene, Incorporated to LWKC are gratefully appreciated.

Reference:

Adami S (1997): Bisphosphonates in prostate carcinoma. *Cancer* 80:1674-9.

Bae SC, Lee KS, Zhang YW, Ito Y (2001): Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. *J Bone Joint Surg Am* 83-A:S48-55.

Chung L, Zhau H (2001): Stromal-Epithelial Interaction: From Bench to Bedside. In Chung L, Isaacs W, Simons J (eds): "Prostate Cancer: Biology, Genetics and New Therapeutics." Totowa, NJ: Human Press, pp 341-364.

Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J (1997): An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. *Mol Endocrinol* 11:148-61.

Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J (1996): Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. *J Biol Chem* 271:6379-88.

Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG (1992): Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. *J Clin Endocrinol Metab* 75:1046-53.

Cramer SD, Chen Z, Peehl DM (1996): Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. *J Urol* 156:526-31.

Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994): Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. *Cancer Res* 54:5474-8.

Denhardt DT, Giachelli CM, Rittling SR (2001): Role of osteopontin in cellular signaling and toxicant injury. *Annu Rev Pharmacol Toxicol* 41:723-49.

D'Souza RN, Aberg T, Gaikwad J, Cavender A, Owen M, Karsenty G, Thesleff I (1999): *Cbfa1* is required for epithelial-mesenchymal interactions regulating tooth development in mice. *Development* 126:2911-20.

Glowacki J, Lian JB (1987): Impaired recruitment and differentiation of osteoclast progenitors by osteocalcin-deplete bone implants. *Cell Differ* 21:247-54.

Hay E, Lemonnier J, Modrowski D, Lomri A, Lasmoles F, Marie PJ (2000): N- and E-cadherin mediate early human calvaria osteoblast differentiation promoted by bone morphogenetic protein-2. *J Cell Physiol* 183:117-28.

Huang W, Shostak Y, Tarr P, Sawyers C, Carey M (1999): Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. *J Biol Chem* 274:25756-68.

Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA (1994): Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. *Endocrinology* 135:1359-66.

Kinto N, Iwamoto M, Enomoto-Iwamoto M, Noji S, Ohuchi H, Yoshioka H, Kataoka H, Wada Y, Yuhao G, Takahashi HE, Yoshiki S, Yamaguchi A (1997): Fibroblasts expressing Sonic hedgehog induce osteoblast differentiation and ectopic bone formation. *FEBS Lett* 404:319-23.

Koenenman KS, Yeung F, Chung LW (1999): Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. *Prostate* 39:246-61.

Lian JB, Stein GS, Stein JL, van Wijnen AJ (1998): Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. *J Cell Biochem Suppl* 31:62-72.

Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET (2001): Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. *Prostate* 47:212-21.

Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LWK (2001): A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. *Cancer Research* 61: 6012-6019.

Mizuno M, Imai T, Fujisawa R, Tani H, Kuboki Y (2000): Bone sialoprotein (BSP) is a crucial factor for the expression of osteoblastic phenotypes of bone marrow cells cultured on type I collagen matrix. *Calcif Tissue Int* 66:388-96.

Nakase T, Takaoka K, Hirakawa K, Hirota S, Takemura T, Onoue H, Takebayashi K, Kitamura Y, Nomura S (1994): Alterations in the expression of

osteonectin, osteopontin and osteocalcin mRNAs during the development of skeletal tissues in vivo. *Bone Miner* 26:109-22.

Nazareth LV, Weigel NL (1996): Activation of the human androgen receptor through a protein kinase A signaling pathway. *J Biol Chem* 271:19900-7.

Sadar MD (1999): Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. *J Biol Chem* 274:7777-83.

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al. (1997): Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89:309-19.

Smart DE, Vincent KJ, Arthur MJ, Eickelberg O, Castellazzi M, Mann J, Mann DA (2001): JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. *J Biol Chem* 276:24414-21.

Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ (2001): Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. *Lancet* 357:336-41.

van Dam H, Huguier S, Kooistra K, Baguet J, Vial E, van der Eb AJ, Herrlich P, Angel P, Castellazzi M (1998): Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation. *Genes Dev* 12:1227-39.

Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT (2000): MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. *J Biol Chem* 275:4453-9.

Xiao G, Wang D, Benson MD, Karsenty G, Franceschi RT (1998): Role of the α 2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. *J Biol Chem* 273:32988-94.

Yamaguchi A, Komori T, Suda T (2000): Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. *Endocr Rev* 21:393-411.

Yeh LC, Adamo ML, Olson MS, Lee JC (1997): Osteogenic protein-1 and insulin-like growth factor I synergistically stimulate rat osteoblastic cell differentiation and proliferation. *Endocrinology* 138:4181-90.


Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999): From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. *Proc Natl Acad Sci U S A* 96:5458-63.

Yeung F, Law W, Yeh CH, Westendorf JJ, Zhang Y, Wang RX, Kao C, Chung LW (2001): Regulation of human osteocalcin (hOC) promoter in hormone-independent human prostate cancer cells. *J of Biological chemistry* xxxxx.

Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW (2000): Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. *J Biol Chem* 275:40846-55.

Yi B, Williams P, al e (2000): Evidence that osteolysis precedes osteoblastic lesions in a model of human osteoblastic metastasis. J Bone Miner Res 15:S177.

Figure 1. A "Ping-Pong" Mechanism of Transcription Factor Activation Through Stromal-Epithelial Interaction: Potential Contributors to Prostate Cancer Bone Metastasis. The homeostasis of localized prostate tumor is maintained by the constant stimulation from the prostate stroma and growth factors released from ECMs which determines the proliferative and differentiative status of tumor epithelium. At this stage, tumor epithelium is considered as androgen-dependent and expressed low levels of OC transcription factors, RUNX2 and Fra2, and bone matrix proteins, OC, OPN, BSP and ON. Upon prostate cancer progression to androgen-independent and metastatic state (such as bone metastasis), a surge of intracellular autocrine and paracrine growth factor signaling results in an elevation of OC transcription factor activity (e.g. increased RUNX2 and Fra2) and elevated level of OC, BSP, OPN and ON. The enhanced RUNX2 and Fra2 is responsible for an overall stimulation of osteoblast proliferation, which then supports tumor growth and survival in the skeleton through greatly increased autocrine and paracrine loops. The co-targeting concept is building upon the observation of increased osteomimetic properties by AI and metastatic prostate cancer cells so that replication-competent Ad vectors can be designed to exert cytotoxic effects on both tumor epithelial and bone stromal cell compartments.



Targeting angiogenic pathways involving tumor–stromal interaction to treat advanced human prostate cancer

Mitchell H. Sokoloff¹ and Leland W.K. Chung^{1,2}

¹*Molecular Urology and Therapeutics Program, Department of Urology and* ²*Department of Cell Biology, University of Virginia, Charlottesville, Virginia, USA*

Key words: prostate cancer, stromal–epithelial interactions, anti-angiogenesis, intermittent androgen suppression

Abstract

Interfering with and preventing tumor angiogenesis is an attractive therapeutic approach for treating cancer metastases. This commentary presents treatment strategies that may enhance the effectiveness of anti-angiogenic therapy by selectively targeting newly sprouting and immature vessels, inhibiting the production of angiogenic factors, and disrupting extracellular matrices. We propose several clinical paradigms, including hormonal ablation, intermittent androgen suppression, chemotherapy, and radiation therapy, that 'injure' nascent vasculature and interrupt the cancer cell–stromal relationship, thereby potentiating the efficacy of experimental anti-angiogenic agents. These stromal–epithelial interactions play an important role in the development, proliferation and dissemination of prostate cancer, as well as guiding the processes of tumor neovascularization. Successful utilization and targeting of tumor angiogenesis requires an increased understanding of tumor cell–stromal cell–endothelial cell relationships, most notably the intricate intracellular signalling cascades mediated by growth factors and the extracellular matrix.

Introduction

Despite advances in prevention and early detection, refinements in surgical technique, and improvements in adjuvant radio- and chemotherapy, the ability to cure many men with prostate cancer remains elusive. This is especially apropos to the successful management of metastatic and recurrent hormone-refractory disease. Clinical protocols using either androgen deprivation therapy or chemotherapeutic agents have shown some promise in treating advanced prostate cancer [1,2]. Unfortunately, the proportion and durability of complete remissions have been limited and new therapeutic approaches are desperately needed.

Stromal–epithelial interactions are paramount to the development, proliferation, and spread of prostate cancer. Studies in our laboratory have established that a bi-directional relationship between tumor cells and their surrounding stroma contributes to the growth and dissemination of prostate cancer [3–5]. These mesenchymal–epithelial interactions are responsible for maintaining the functional integrity of the

normal adult prostate gland. Irregularities in the constituents of the stromal–epithelial milieu or aberrations in their interactions can induce genomic instability, enhance tumor cell proliferation, and drive both metastatic spread and progression to a hormone-refractory state. Consequently, novel therapeutic protocols are being developed that target not only prostate tumor epithelial components, but surrounding stromal and extracellular matrix (ECM) elements as well.

For a prostate cancer to grow and metastasize, endothelial cells from this surrounding stroma must be recruited to form an endogenous microcirculation to support the developing neoplastic mass [6,7]. Similar angiogenic processes are necessary at sites of metastasis if disseminated tumor cells are to become securely entrenched and, subsequently, propagate. Although prostate cancer cells produce inherent pro-angiogenic signals, integration of downstream signalling involving soluble factors and stromal and ECM components are critical to promoting and maintaining neovascularization [8].

Stromal-epithelial cell injury may potentiate anti-angiogenic therapy

We have recently demonstrated that *squalamine*, an anti-angiogenic sterol isolated from shark liver, has potent anti-prostate cancer activity [11]. When squalamine was applied concomitantly with androgen withdrawal in a human prostate cancer xenograft model, an absolute and lasting eradication of both PSA and subcutaneous tumors was achieved. No such result was observed in intact tumor-bearing animals or in tumor-bearing animals treated with squalamine post-castration, yet subsequent to the appearance of androgen independent lesions. Immunohistochemical staining of responding and non-responding tumors indicated that combined squalamine and castration substantially diminished integrin $\alpha_v\beta_3$ expression. Additional histologic data established that squalamine's actions were most potent in preventing proliferation of the freshly sprouting, phenotypically immature blood vessels that, we believe, emerge in the tumor tissue as it acquires hormone independence. This finding corroborated prior studies which have determined that squalamine's efficacy is significantly enhanced when tumor vasculature and cancer cells are 'injured' immediately antecedent to its application [12,13].

Accordingly, we have developed two theories to explain the powerful anti-angiogenic as well as anti-prostate cancer effects of coincident androgen ablation and squalamine administration. First, androgen deprivation, may so effectively 'stun' the stromal-epithelial environment that normally prevalent and active pro-angiogenic factors are diminished, inactivated, or eradicated. At this juncture, the diminution of angiogenic forces may be sufficient enough that the otherwise ineffectual squalamine (if used in the absence of hormone-ablation) is consequently rendered potent. Alternatively, during the immediate post-orchietomy rejuvenated proliferative phase (when stromal-mediated and autonomous epithelial tumor cell growth is actively acquiring hormone independence) the cellular and vascular architecture may become somewhat pliable and plastic, predisposing these precarious cells to either anti-angiogenic or cytotoxic effects of squalamine.

These interesting observations and speculations have led us to develop the following hypothesis: that the effectiveness of anti-angiogenic agents can be increased when applied coincident with other

therapeutic interventions that injure components of the stromal-epithelial milieu. This premise is particularly plausible considering that most pro-angiogenic factors are located within the stromal milieu, either as soluble or ECM-bound factors, which affects survival of tumor epithelium.

Tumor-stromal interactions and angiogenesis

The outcome of a patient with prostate cancer ultimately depends upon the tumor's capacity for unhindered growth, local invasion, and the establishment of distant metastasis. Local factors, produced by mesenchyme, epithelial cells, or as a consequence of bi-directional mesenchymal-epithelial interactions between prostate tumor and stromal cells, are necessary for such proliferative, invasive, and migratory events [14].

Numerous cytokines and growth factors have been implicated in either enhancing or impairing a given prostate tumor's inherent tumorigenic and metastatic phenotype [15]. While some act directly upon the tumor cells, others influence prostate tumor cell proliferation by modulating their interactions with the extracellular matrix interactions through either soluble or matrix-associated signaling. This can significantly alter tumor cell heterogeneity with the propensity of selecting androgen-independent and metastatic variants.

Angiogenesis

Angiogenesis refers to the formation of new blood vessels from pre-existing, nascent vasculature. It is a multistep sequential process involving the recruitment and proliferation of endothelial cells, their subsequent migration to the tumor mass, morphogenesis into a tubular structure, and maturation into a stable structure [16,17]. It is important to note that the structure of tumor vessels differ from those of normal tissues, especially with regard to cellular composition, tissue integrity, vascular permeability, and regulation of cell proliferation and apoptosis [18]. It is presumed that these many differences may impart selective susceptibility of tumor vessels to the effects of anti-angiogenic agents.

The establishment and maintenance of such a vascular supply is imperative to prostate carcinogenesis and involves the cooperation of a variety of molecules either constituting or inhabiting the ECM. A variety of

Recent studies report that up to 50 percent of patients who were thought to have organ-confined lesions were discovered to be understaged subsequent to surgery [43–45]. As a result, the majority of men with prostate cancer will eventually develop disseminated disease [46]. In addition to causing severe pain and morbidity, such metastatic disease is the primary cause of death in men with prostate cancer [47]. Androgen ablation therapy is the most widely accepted therapy for men with metastatic cancer. Because of its limited duration, however, certain chemotherapeutic agents have been incorporated in the treatment of advanced, hormone-refractory disease. Furthermore, radiation therapy (with or without hormonal therapy) is commonly used to treat locally-invasive lesions that are felt to be incurable by surgical means.

With regard to prostate cancer, androgen ablation therapy, chemotherapy, and radiation therapy share two common traits. First, by themselves, they customarily behave as temporizing agents resulting in disease remission, but are generally ineffective in curing advanced disease. Second, in addition to directly damaging prostate cancer cells, each of these treatment modalities induces injury to the surrounding stroma and extracellular matrix. In fact, studies demonstrating improved outcomes in men with prostate cancer after treatment with combined radiation and androgen ablation therapy attribute these findings, in part, to the resultant interference with the stromal-epithelial relationship [48]. Furthermore, p53, which can act as a radiosensitizer, may enhance the efficacy of radiation therapy via its anti-angiogenic properties, such as inducing expression of the anti-angiogenic ECM component, thrombospondin-1 [49,50]. Because of their individual and independent abilities to injure components of the extracellular milieu, androgen ablation therapy, chemotherapy, and radiation therapy are ideal therapeutic approaches to investigate for use in concert with anti-angiogenic agents to treat men with, or at risk for developing, advanced prostate cancer.

Taking all three of these treatment modalities into consideration, we can now reiterate our hypotheses as to how androgen ablation therapy, chemotherapy, and radiation therapy may induce sufficient injury to the stromal-epithelial environment that the effects of the subsequent utilization of anti-angiogenic agents would be potentiated. First, damage to the homeostatic cellular components of the stromal-epithelial milieu might decrease, or even completely suppress, the secretion of soluble pro-angiogenic factors and intracellular

signaling of pro-angiogenic components, inhibiting many of the steps required for neovascularization. Such alterations in this constituency could greatly increase the sensitivity of the tumor to anti-angiogenic therapy. Second, injury to the vascular endothelial cells within the stroma could result in the immediate destruction of the tumor vasculature (resulting in the cessation of blood flow to the cancer cells) or weaken the vessels sufficiently that their susceptibility to attack by a second (anti-angiogenic) agent is increased. Furthermore, damage to established vessels might induce the formation of new vasculature to nourish and sustain both the tumor mass and the surrounding tissues, or alter the phenotype incipient vasculature so that it acquires the more immature characteristics of newer vessels. It is generally accepted that these younger, more immature vessels are most-susceptible to anti-angiogenic insult [51]. Third, immediately following intervention, some stromal and epithelial tumor cells are likely to overcome their injuries and begin to initiate repair pathways, in which they recapitulate a phenotypically younger and more unstable configuration. As the cellular architecture becomes increasingly precarious, these cells are more apt to be affected by the anti-angiogenic agents.

Androgen ablation therapy

Our data from the LNCaP-castrate xenograft model confirmed that squalamine's actions were most potent on the freshly sprouting, immature blood vessels that, we believe, developed during a rejuvenated proliferative phase of those prostate tumor cells acquiring hormone independence. The effect was independent of serum VEGF levels. There is ample evidence that androgen application can stimulate vasculogenesis whereas androgen deprivation can inhibit neovascularization, allegedly the result of increased or decreased VEGF production (respectively). Folkman has demonstrated that VEGF production by LNCaP cells is under tight regulation by androgen and that androgen withdrawal inhibited hypoxic induction of VEGF [52]. Isaacs and associates have demonstrated that the activity of Linomide, an oral anti-angiogenic agent which has demonstrated effectiveness in suppressing human prostate cancer in preclinical animal studies, was potentiated by concurrent androgen ablation, presumably due to down-regulation of VEGF [30].

It was recently demonstrated that prostate gland growth in a rat model was regulated by the vascular

of anti-angiogenic agents. By cyclically applying and withdrawing androgen, intermittent androgen blockade systematically injures tumor and vascular cells over a prolonged period of time. This repeated stress should prime them for the actions of an anti-angiogenic agent, resulting in the destruction of both tumor cells and the surrounding stroma.

Chemotherapy and radiation therapy

External beam radiotherapy, as well as brachytherapy, is frequently applied to the treatment of local and locally-advanced prostate cancer. Furthermore, radiation therapy is commonly used to treat symptomatic metastases. Radiation induces significant injury to both tumor and stromal cells [61,62]. There is often scarring and destruction of nascent vasculature, as well as damage to the surrounding stromal and ECM components. In both situations, much akin to androgen ablation therapy, the stromal-epithelial milieu initially experiences significant injury with damage to stromal cells as well as pro-angiogenic signals. With time, however, these cells attempt to repair the radiation-induced damage, and the stromal-epithelial compartments undergo neovascularization with the potential to support a tumor recurrence. Similarly, applying taxol and estramustine, two currently used agents in prostate disease and as a paradigm for other chemotherapeutic regimens, will similarly induce injury of both endothelial and epithelial tumor cells [63,64]. We propose that the application of an anti-angiogenic agent coincident with radio- or chemotherapy induced injury could inhibit stromal neovascularization and prevent tumor recurrence.

Concluding remarks

Anti-angiogenic agents have shown promise in several preclinical studies of prostate cancer. In our own experience squalamine, an aminosterol with anti-angiogenic properties, has demonstrated effectiveness when applied concomitant with castration. As many of the pro-angiogenic influences present in prostate carcinogenesis reside with the stromal-tumor cell-ECM environment, it is not surprising that castration, which induces widespread damage within the stroma (in addition to having direct cytotoxic effects), would potentiate the activity of an anti-angiogenic agent. In this commentary, we speculate that the potency of

anti-angiogenic agents will be most pronounced when applied in conjunction with other therapeutic modalities that maximally injure the stromal and ECM. For now, this includes intermittent androgen suppression, radiation therapy, and chemotherapy, but may, with time, be applicable to gene therapy and novel molecular approaches being developed for the treatment of both localized and advanced human prostate cancer.

References

1. Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. *Eur J Canc* 33: 566-574, 1997
2. Bane RL, Torti FM: Endocrine therapy for prostate cancer. *Canc Treat Res* 94: 69-87, 1998
3. Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth *in vivo* by prostate and bone fibroblasts. *Canc Res* 51: 3753-3761, 1991
4. Chung LWK: Implications of stromal-epithelial interaction in human prostate cancer growth, progression, and differentiation. *Sem Canc Biol* 4: 183-192, 1993
5. Chung LWK: Stromal-epithelial interactions dictate prostate cancer androgen independent metastatic progression. *Canc Det Prev* 22 (Supplement 1): 57-58, 1998
6. Ellis LM, Fidler IJ: Angiogenesis and Metastasis. *Eur J Canc* 32A: 2451-2460, 1996
7. Weinstat-Saslow D, Steeg P: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. *FASEB J* 8: 401-407, 1994
8. Polverini PJ: How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. *Eur J Canc* 32A: 2430-2437, 1996
9. Folkman J: Clinical applications of research on angiogenesis. *New Engl J Med* 333: 1757-1763, 1995
10. Boehm T, Folkman J, Bowder T, O'Reilly MS: Anti-angiogenic therapy of experimental cancer does not induce drug resistance. *Nature* 390: 404-407, 1997
11. Sokoloff MH, Bradley MJ, Zhau HE, Williams JJ, Chung LWK: Downregulation of integrin $\alpha_v\beta_3$ expression by squalamine obliterates advanced human prostate cancer. Submitted
12. Sills AK, Williams JJ, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zaslowski M, Brem H: Squalamine inhibits angiogenesis and solid tumor growth *in vivo* and perturbs embryonic vasculature. *Canc Res* 58: 2784-2792, 1998
13. Teicher BA, Williams JJ, Takeuchi H, Ara G, Herbst RS, Buxton D: Potential of the aminosterol squalamine in combination therapy in rat mammary carcinoma and murine Lewis lung carcinoma. *Anticancer Res* 18: 2567-2573, 1998
14. Brooks PC: Role of integrins in angiogenesis. *Eur J Canc* 32A: 2423-2429, 1996

51. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial derived growth factor mediated signaling in mouse mesentery vascular endothelium. *Canc Res* 58: 1278-1284, 1998
52. Folkman J: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence (editorial). *Endocrinol* 139: 441-442, 1998
53. Frank-Lissbrant I, Haggstrom S, Damberg J-E, Bergh A: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. *Endocrinol* 139: 451-456, 1998
54. Haggstrom S, Wikstrom P, Bergh A, Damberg J-E: Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. *Prostate* 36: 71-79, 1998
55. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. *Proc Natl Acad Sci* 95: 10820-10825, 1998
56. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate specific antigen gene in the LNCaP prostate tumor model. *J Steroid Biochem Mol Biol* 58: 139-146, 1996
57. Theyer G, Hamilton G: Current status of intermittent androgen suppression in the treatment of prostate cancer. *Urol* 52: 353-359, 1998
58. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer. *Urol* 47: 956-961, 1995
59. Higano CS, Ellis W, Russell K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. *Urol* 48: 800-804, 1996
60. Zhou HE, Chang S-M, Chen B-Q, Wang Y-L, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK: Androgen-repressed phenotype in human prostate cancer. *Proc Natl Acad Sci* 93: 15152-15157, 1996
61. Fajardo LF, Berthrong M: Vascular lesions following radiation. *Path Ann* 23: 297-300, 1988
62. Fajardo LF: Morphology of radiation effects on normal tissues. In: Perez CA, Brady LW (eds) *Principles and Practice of Radiation Oncology*. Lippincott, Philadelphia, 1997, pp 143-154
63. Hudes OR, Natha F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. *J Clin Oncol* 15: 3156-63, 1997
64. Pienta KJ, Smith DC: Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. *Semin Oncol* 24 (Supplement 5): 72-75, 1997

Address for correspondence: Mitchell H. Sokoloff, Department of Urology, Box 422, Health Sciences Center, University of Virginia, Charlottesville, Virginia 22908, USA; Tel: 804 243 6512

CURRICULUM VITAE

Revised 10/12/01

Name: Leland W. K. Chung, Ph.D.**Office Address:** Molecular Urology and Therapeutics Program
Department of Urology
Winship Cancer Institute
Emory University
1365B Clifton Road, N.E., Suite B4100
Atlanta, GA 30322Ph: (404) 778-4319
Fax: (404) 778-3965**E-mail Address:** lwchung@emory.edu
Leland_Chung@emory.org**Birth Date & Place:** September 30, 1940
Kwelin, Kwangshi, CHINA**Citizenship:** United States**Title & Affiliation:** *Primary Appointment*
Professor of Urology, Director of Molecular Urology and
Therapeutics Program, Department of Urology
John Kluge Distinguished Professor in Urology and Cancer
Research
University of Virginia, Charlottesville, Virginia
1995-present*Secondary Appointment*
Professor of Cell Biology, Department of Cell Biology,
University of Virginia, Charlottesville, Virginia
1996-present**Academic & Professional Appointments:**

2001-Present Professor of Urology, Biochemistry and Winship Cancer Institute
Director, Molecular Urology and Therapeutics Program
Director, Division of Research
Emory University, Department of Urology
Atlanta, GA 30322

1996-2001 Professor of Cell Biology
University of Virginia, Department of Cell Biology
Charlottesville, Virginia

1995-1996	Professor of Urology Director, Molecular Urology and Therapeutics Program University of Virginia, Department of Urology Charlottesville, Virginia
1990-1995	Professor of Urology and Biochemistry and Molecular Biology University of Texas, M. D. Anderson Cancer Center Department of Urology and Biochemistry and Molecular Biology Houston, Texas
1986-1990	Associate Professor of Urology and Biochemistry and Molecular Biology University of Texas, M. D. Anderson Cancer Center Department of Urology and Biochemistry and Molecular Biology Houston, Texas
1980-1986	Associate Professor of Pharmacology University of Colorado, School of Pharmacy Boulder, Colorado Associate Professor of Pharmacology University of Colorado, School of Medicine Denver, Colorado
1977-1980	Assistant Professor of Pharmacology University of Colorado, School of Pharmacy Boulder, Colorado
1972-1977	Assistant Professor of Pharmacology McGill University, Department of Pharmacology and Therapeutics Montreal, Quebec, Canada

Administrative Appointments:

1995-Present	Director, Molecular Urology and Therapeutics Program University of Virginia, Department of Urology Charlottesville, Virginia
1986-1995	Director, Urology Research Laboratory University of Texas, M. D. Anderson Cancer Center Houston, Texas
1980-1986	Director, Graduate Studies University of Colorado, School of Pharmacy Boulder, Colorado

Education:

1965-1969	Ph.D., University of Oregon Health Sciences Center Department of Pharmacology Portland, Oregon
1963-1965	M.S., Oregon State University Department of Biochemistry Corvallis, Oregon
1958-1962	B.S., National Taiwan University Department of Agricultural Chemistry Taipei, Taiwan

Postgraduate Training:

1969-1972	Postdoctoral Fellow Department of Pharmacology and Experimental Therapeutics Johns Hopkins University School of Medicine and James Buchanan Brady Urological Institute Baltimore, Maryland Donald S. Coffey, Ph.D., Professor of Urology, Pharmacology, Oncology and Molecular Sciences
-----------	---

Committee Memberships:*National and International*

1996-present	Scientific Advisor, Eli Lilly Research Laboratory Human Genome Project
1995-present	Scientific Advisor, University of Michigan Comprehensive Cancer Center SPORE Grant
1993-present	Member, NASA/Biomedical Sciences Investigator's Committee
1993-present	Scientific Advisory Board Member, CaPCURE Foundation
1990-present	Ad hoc Member, Dutch Cancer Society, Canadian Cancer Society, British Cancer Society, and Hong Kong University Systems' Grant Review
1986-present	Ad hoc Member, NCI, NIH and Veterans Administration Research Grant Review
1997-1998	Organizer and Member, NCI-Sponsored Prostate Cancer Progress Review Committee
1997-1998	Panel Member, U.S. Army Integration of Prostate Cancer
1997-1998	Member, Program Committee of an International Society for Andrology Meeting
1993-1996	Member, NIH Experimental Therapeutic I Study Section
1996	Chairman, Gordon Research Conference on Reproductive Tract Biology
1996	Organizer, 7th NCI-Sponsored Prostate Neck Meeting on Prostate Cancer
1996	Organizer, Workshop on Endocrine Therapy of Advanced Prostate Cancer

1990-1995	Consultant, American Urologic Association, Education and Research Committee
1989-1993	Chairman and Member, Program Committee, Annual Meeting of the Society for Basic Urologic Research
1991	President, Society for Basic Urologic Research
1991	Member, Program Committee, NIH-Sponsored International Symposium on Prostate Growth
1988	President, Society of Chinese Bioscientists in America

Regional & State

1999-present	Member, General Clinical Research Advisory Committee
1995-present	Member, Ph.D. Student Thesis Committees
1994-1995	Member, PRS Scientific Review Committee
1993-1995	Chairman, Institutional Faculty Classification Committee (Equivalent to Tenure and Promotion Committee)
1991-1995	Departmental Representative, Institutional Faculty Senate
1990-1995	Chairman, Admissions Committee for the Reproductive Biology Program, Graduate School of Biomedical Sciences, University of Texas Health Sciences Center, Houston
1988-1995	Alternate Member, Executive Committee of the Science Faculty
1988-1995	Member, Program Advisory Committee, Reproductive Biology Program, Graduate School of Biomedical Sciences
1988-1995	Member, Membership Committee and the Faculty Enrichment Committee, Minority Faculty Association
1987-1995	Member, Institution Recombinant DNA Subcommittee
1992-1993	Member, Institutional Faculty Classification Committee
1988-1991	Member, Institutional Research Grant Committee
1987-1991	Member, Institutional Research Committee
1988-1989	Member, Status of Minority Women Faculty and Staff Committee
1987-1989	Member, Tenure and Promotion Committee, Division of Surgery

Consultantships:

1999-present	DirectGene, Inc., Annapolis, Maryland
1996, 1989, 1987, 1985, and 1983	Eli Lilly Research Laboratory, Indianapolis, Indiana
1988	Sterling Research Group, Great Valley, Pennsylvania
1988	Laboratories DEBAT, Paris, France
1986	Genentech, Inc., San Francisco, California; Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey

Editorships & Editorial Boards:

2000-present	Editorial Board, <i>The Prostate</i>
1997-present	Editorial Board, <i>Prostate Cancer and Prostatic Diseases</i>
1996-present	Editorial Board, Basic Science Member, <i>Urology Journal</i>
1994-present	Managing Editor, <i>Urologic Oncology</i>
1994-present	Editorial Board Member, <i>International Journal of Oncology</i>
1992-1995	Editorial Board Member, <i>Journal of Andrology</i>

Manuscript Reviewer:

1972-present	<i>American Journal of Physiology and Pharmacology Biochemical and Biophysical Acta</i> <i>Biochemical Pharmacology</i> <i>Biology of Reproduction</i> <i>Blood</i> <i>British Journal of Cancer</i> <i>Canadian Journal of Physiology</i> <i>Cancer</i> <i>Cancer Research</i> <i>Developmental Pharmacology and Therapeutics</i> <i>Drug Metabolism and Disposition</i> <i>Endocrinology</i> <i>International Journal of Cancer</i> <i>International Journal of Oncology</i> <i>Pharmacology and Experimental Therapeutics</i> <i>Proceedings of the National Academy of Sciences</i> <i>Journal of Andrology</i> <i>Journal of Biological Chemistry</i> <i>Journal of Cell Biology</i> <i>Journal of Clinical Investigation</i> <i>Journal of Pharmacology</i> <i>Journal of Steroid Biochemistry</i> <i>Journal of Urology</i> <i>Molecular and Cellular Biochemistry</i> <i>Molecular Endocrinology</i> <i>Molecular Pharmacology</i> <i>Nature Medicine</i> <i>Prostate Cancer and Prostatic Diseases</i> <i>Science</i> <i>The Prostate</i> <i>Urologic Oncology</i> <i>Urology Gold Journal</i>
--------------	---

Honors & Awards:

2000	Wu Jieping Medical Science Award, Beijing, China
1995-present	John Kluge Distinguished Professor in Urology and Cancer Research, University of Virginia, Charlottesville
1991-present	Honorary Professor, Beijing Medical University; Ximen University; Xian Medical University; Chongqing Third Military University
1993-1996	Member, NIH Experimental Therapeutics I Study Section
1996	Chairman, Gordon Research Conference on Reproductive Tract Biology
1994-1995	Hubert L. and Olive Stringer Professorship in Cancer Research, University of Texas MD Anderson Cancer Center, Houston
1993, 1995	Dean's Teaching Award for Outstanding Achievements in Teaching, University of Texas Health Sciences Center, Graduate School of Biomedical Sciences, Houston
1993	Ben Rogers Award for Excellence in Research

	University of Texas MD Anderson Cancer Center, Houston
1992	President, Society for Basic Urologic Research
1988	President, Society of Chinese Bioscientists in America
1984-1985	Faculty Fellowship Award, University of Colorado, Boulder
1984	Member, Rho Chi Honorary Pharmacy Society
1970-1972	Postdoctoral Fellowship, National Institutes of Health

Society Memberships:

1985-1995	American Society of Andrology
1972-present	American Pharmacology and Experimental Therapeutics
1985-present	Society of Chinese Bioscientists in America
1986-present	American Association for Cancer Research
1986-present	American Urological Association
1990-present	Society for Basic Urologic Research

Research Focus:

- Tumor and microenvironment interaction that dictates cancer growth and progression
- Novel genetic and molecular targeting strategies for the treatment of localized and disseminated prostate cancer
- Profiling of tumor cell growth and gene expression under 2-D and 3-D growth conditions and in animal models
- Function of transcriptional factors that regulate tumor cell growth, differentiation and metastasis
- Normal and neoplastic prostate biology and development

Patents:

Issued

1997	5,679,636: Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
1998	7,518,282: Novel bone and prostate-derived protein factors affecting prostate cancer growth, differentiation and metastasis
1998	5,728,815: Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
1998	5,772,993: Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
1999	5,874,305: Androgen Repressed Metastatic Human Prostate Cancer Cell Line
2000	6,159,467: In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy

Pending

Identification, cloning and characterization of a novel gene
Viral processing techniques
Bone cancer therapy
Gene expression directed by a novel PSA promoter
Bone matrix protein promoters targeting of prostate cancer
Fetal urogenital sinus expressed sequences

Current Grant Support:

National Institutes of Health, Principal Investigator. R01-CA76620-01. "Extracellular matrix-integrin signaling in prostate cancer," \$506,262 – 04/01/99 to 01/31/04

Department of Defense Prostate Cancer Initiative Idea Award, Principal Investigator. DAMD 17-00-1-0526. "Accelerated tumor cell death by angiogenic modifiers," \$375,000 – 06/01/00 to 05/30/03

National Aeronautics and Space Administration, Principal Investigator. NRA-97-HEDS-02-126. "Modeling prostate cancer skeletal metastasis and gene therapy," \$657,000 – 02/01/99 to 09/30/02

National Institutes of Health, Principal Investigator. CA 85555-01. "Ad-OC-TK/Val gene therapy clinical correlates," \$500,000 – 05/01/00 to 04/31/02

DirectGene, Inc. (Industrial), Principal Investigator, "Tissue-specific and tumor-restricted promoter-directed therapeutic gene expression in pre-clinical models of human prostate cancer," \$300,000 – 10/01/00 to 09/30/01

Eluysis (Industrial), Co-Principal Investigator. "Use of novel tumor-specific antigens to treat and diagnose cancer," \$283,000 – 07/15/99 to 07/31/01

Kluge Foundation, Principal Investigator. "Molecular staging and therapy," \$1,000,000 – 1998-present

National Institutes of Health, Sub-Contract with Johns Hopkins University. "SPORE in prostate cancer," \$85,000 – 1992-present

Past Grant Support: (past 5 years)

Introgen Therapeutics, Principal Investigator. "Brachygene therapy for prostate cancer," \$90,000 – 02/01/00 to 02/01/01

National Cancer Institute, Subcontract. Cell Culture Core Facility, \$58,062 – 02/00 to 01/01

CaPCURE Corporation, Principal Investigator. "Gene therapy strategy to enhance the targeting of prostate cancer bone metastasis using controlled tumor-specific promoters," \$100,000 – 01/01/00 to 12/31/00

National Institutes of Health, Principal Investigator. "Stromal factors in prostate growth and progression," \$999,398 / 4 years – 02/01/97 to 01/31/00

Microgravity Biotechnology: Research and Flight Experiment – NASA-Johnson Space Center, Principal Investigator. "Microgravity-simulated prostate cell culture," \$794,647 / 4 years – 09/15/95 to 09/14/99

Hoffmann-LaRoche, Inc., Principal Investigator. "Evaluation of vitamin D3 analogs on the growth and differentiation of a mouse model of human prostate cancer," \$185,771 – 01/15/97 to 01/14/99

National Institutes of Health, Principal Investigator. "Identification of steroid-responsive mesenchymal genes," \$912,159 / 5 years – 09/30/93 to 09/29/98

National Institutes of Health, Principal Investigator. RO1CA64863. "Prostate cancer metastasis: Role of stroma," \$1,315,893 – 07/01/94 to 06/31/98

CaPCURE, Principal Investigator. "Development of novel therapies for human prostate cancer bone metastasis," \$100,000 – 01/01/97 to 12/31/97

Daiichi Pharmaceutical Corporation, Principal Investigator. #04-91-02631. "Effects of sulphated polysaccharide peptidoglycan complex tecogalan on the Growth of Human prostate cancer *in vivo*," \$165,000 – 05/04/94 to 05/04/97

Daiichi Pharmaceutical Corporation, Principal Investigator. "Evaluation of the anti-tumor effects of DX-8951F," \$82,825 – 02/01/96 to 02/01/97

CaPCURE, Principal Investigator, "Therapeutic Approaches for the Treatment of Human Prostate Cancer Metastasis," \$175,000 / 2 years – 01/02/95 to 01/02/97

National Institutes of Health, Co-Principal Investigator. "Training of academic urologists," Total Direct Costs: \$696,000 / 5 years – 07/15/91 to 06/30/96

Industrial Group, Co-Principal Investigator. "Prostate cancer prevention with Edi-Pro protein diet," \$90,000 – 05/01/94 to 04/31/96

National Institutes of Health, Co-Principal Investigator. "*neu* oncogene in human prostate cancer progression," \$321,621 / 3 years – 05/01/93 to 04/31/96

National Institutes of Health, Co-Principal Investigator. "Molecular analysis of human prostate cancer progression," \$349,514 / 3 years – 05/01/93 to 03/31/96

CaPCURE, Principal Investigator. "Therapeutic intervention of metastatic human prostate cancer," \$200,000 / 2 years – 01/02/94 to 01/02/96

National Institutes of Health, Principal Investigator. "Sex steroids and growth factors in prostatic hyperplasia," \$460,323 / 3 years – 08/01/91 to 07/31/95

National Institutes of Health, Principal Investigator. "Cellular interactions and prostate growth," \$799,496 / 6 years – 12/01/88 to 11/30/95

Formal Teaching:

1995-present	Lecturer, Cancer Biology for Graduate Students
1989-1995	Coordinator, Genitourinary Cancer Biology Course for Urology, Pathology, and Medical Oncology Group
1987-1995	Reproductive Biology Elective, Graduate School of Biomedical Sciences
1987-1990	Coordinator, Research Forum for Graduate and Postgraduate Students, Graduate School of Biomedical Sciences
1977-1986	Lecturer, Graduate Courses Drug Metabolism and Toxicity, Molecular Endocrinology, Hormones and Neoplastic Growth, Sexual Differentiation During Development, and Tissue and Cellular Interaction University of Colorado, School of Pharmacy, and School of Medicine, Boulder and Denver, Colorado
1977-1986	Lecturer, Undergraduate Courses Endocrine Pharmacology, Cancer Chemotherapy, Antibiotic Therapy, Cardiovascular Pharmacology, Clinical Chemistry University of Colorado, School of Pharmacy, and School of Medicine, Boulder and Denver, Colorado

Supervisory Teaching: (past 5 years)

Ph.D. Students

1996-present	Fan Yeung, B.S., University of Virginia
1996-present	Bekir Cinar, B.S., D.M.V., University of Virginia

1993-2000	Song Chu Ko, M.D., Ph.D., University of Texas Graduate School of Biomedical Sciences
1993-2001	Robert Sikes, Ph.D., University of Texas Graduate School of Biomedical Sciences

Post-doctoral Fellows

2000-present	Masayuki Egawa, M.D., Assistant Professor, Kanazawa University, Japan
2000-present	Brian Nicholson, M.D., University of Virginia, Charlottesville
1999-present	Shigeji Matsubara, M.D., Postdoctoral Fellow, Kobe University School of Medicine, Japan
1999-present	Chia-Ling Hsieh, Ph.D., Assistant Professor, Emory University, Atlanta
1998-present	Magnus Edlund, Ph.D., Assistant Professor, Emory University, Atlanta
1998-present	Li Miao, M.D., Research Associate, University of Virginia
2000-2001	Moon-Soo Park, M.D., Assistant Professor, Seoul Municipal Boramae Hospital
1998	Jian-Guang Zhou, M.D., Assistant Professor, Institute of Biotechnology, Beijing, China
1998-2000	Yoshitaka Wada, M.D., Assistant Professor, Kobe University School of Medicine, Japan
1998-2000	Sheng-Wen Li, M.D., Assistant Professor, Norman Bethune University, Changchun, China
1998-2000	Chaeyong Jung, D.V.M., Ph.D., Postdoctoral Fellow, Indiana University, Indianapolis
1998-2000	Kenneth Koeneman, M.D. (AFUD Scholar), Assistant Professor, University of Texas Southwestern Medical Center, Dallas
1998-2000	Qinong Ye, Ph.D., Research Associate, University of Virginia
1997-1999	Mitchell Sokoloff, M.D. (AFUD Scholar), Assistant Professor, University of Chicago
1996-1999	Thomas A. Gardner, M.D. (AFUD Scholar), Assistant Professor, Indiana University, Indianapolis
1993-1999	Chinghai Kao, Ph.D., Associate Professor, Indiana University, Indianapolis
1998-1999	Chang-Ling Li, M.D., Assistant Professor, Chinese Academy of Medical Sciences, Beijing, China
1996-1999	Hong Woo Rhee, M.D., Assistant Professor, Kangnam St. Mary's Hospital, Seoul, Korea
1986-1998	Shi-ming Chang, Ph.D., Retired
1996-1998	Tadayuki Miyamoto, M.D., Assistant Professor, Kobe University School of Medicine, Japan
1995-1997	Jun Cheon, M.D., Professor, Korea University Hospital, Seoul, Korea
1995-1997	Tony Wu, M.D., Assistant Professor, Veterans General Hospital, Kaohsiung, Taiwan
1995-1996	David Corral, M.D., Assistant Professor, Roswell Park Cancer Institute, Buffalo, NY
1994-1995	Rodney Davis, M.D., Assistant Professor, Tulane University New Orleans, LA

1993-1995	Craig Hall, M.D. , Associate Professor, Wake Forest University, Winston-Salem, NC
1993-1995	David Kleinerman, M.D., Assistant Professor, UTMD Anderson Cancer Center, Houston TX
1993-1995	George Thalmann, Ph.D., Associate Professor, Inselspital, Universitätsklinik, Bern, Switzerland
1996-1999	Yen-Chuan Ou, M.D., Assistant Professor, Taichung Veterans General Hospital, Taiwan
1996-1999	Se Joong Kim, M.D., Assistant Professor, Ajou University School of Medicine, Suwon, Korea
1996-1998	Akinobu Gotoh, M.D., Assistant Professor Kobe University School of Medicine, Japan
1995-1998	H.Q. Zhang, Ph.D., Research Associate, Karolinska Institute, Sweden
1995-1998	Yu-ling Wang, D.V.M., Research Associate, Karolinska Institute, Sweden
1995-1996	Christopher Evans, M.D., Assistant Professor, University of California at Davis, CA
1995-1996	Christopher Wood, M.D. (AFUD Scholar), Assistant Professor, UTMD Anderson Cancer Center, Houston, TX
1994-1995	Michael Chen, M.D. (AFUD Scholar), Assistant Professor, UTMD Anderson Cancer Center, Houston TX
1994-1995	Ling-Jun Ho, M.S., Assistant Professor, Taiwan Veterans General Hospital, Taipei, Taiwan
1993-1995	Weitao Song, Ph.D., Research Associate, Baylor College of Medicine, Houston TX

Bibliography:

Published and Accepted Articles in Refereed Journals

1. Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HYE, and Chung LWK. Integrin expression and utilization by LNCaP prostate cancer cells on laminin substrata. *Cell Growth and Differentiation* 12:99-107, 2001.
2. Hsieh C-L and Chung LWK. New perspectives of prostate cancer gene therapy: molecular targets and animal models, *Eukaryotic Gene Expression*, in press.
3. Koenenman KS, Kao C, Ko S-C, Yang L, Wada Y, Kallmes DA, Gillenwater JY, Zhau HYE, Chung LWK, and Gardner TA. Osteocalcin directed gene therapy for prostate cancer bone metastasis. *World J. of Urol.* 18:102-110, 2000.
4. Komata T, Kondo Y, Koga S, Ko S-C, Chung LWK and Kondo S. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. *Gene Therapy* 7:2071-2079, 2000.
5. Thalmann GN, Sikes RA, Wu TT, DeGeorges A, Chang S-M, Ozen M, Pathak S, and Chung LWK. The LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. *The Prostate*. 44:91-013, 2000.
6. Ye Q, Chung LWK, Cinar B, Li S and Zhau HYE. Identification and characterization of estrogen receptor variants in prostate cancer cell lines. *J Steroid Biochem and Mol Biol* 75(1):21-31, 2000.
7. Ye Q, Chung LWK, Cinar B, Li S and Zhau HYE. Identification of a novel FAS/ER-alpha fusion transcript expressed in human cancer cells. *Biochimica et Biophysica Acta* 1493:373-377, 2000.

8. Yeung F, Li X, Ellett J, Trapman J, Kao C, and Chung LWK. Regions of prostate specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. *J. Biol Chem.* 275(52):40846-40855, 2000.
9. Zhau HYE, Li CL, and Chung LWK. Establishment of human prostate cancer skeletal metastasis models. *Cancer Suppl.* 2995-3001, 2000.
10. Degeorges A, Wang F, Frierson HF, Jr, Seth A, Chung LWK, and Sikes RA. Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. *Cancer Res.* 59(12):2787-90, 1999.
11. Hyytinen E-R, Frierson HF, Boyd JC, Chung LWK, and Dong J-T. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. *Genes, Chromo., and Cancer.* 25(2):108-14, June 1999.
12. Hyytinen ER, Frierson HF, Sipe TW, Li C-L, Degeorges A, Sikes RA, Chung LWK, and Dong J-T. Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. *The Prostate.* 41:190-195, 1999.
13. Koeneman K, Yeung F, and Chung LWK. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. *The Prostate.* 39(4):246-261, 1999.
14. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LWK, and Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. *Urology.* 53(5):1063-1069, 1999.
15. Rhee HW, Chang S-M, Zhau HE, Pathak S, Multani AS, Visakorpi T, Gardner TA, and Chung LWK. Permanent phenotypic and genomic changes of a human prostate cancer cell line LNCaP through cellular interaction with prostate or bone fibroblasts in vivo or under microgravity-simulated growth conditions. *In Vitro Biol.*, in press.
16. Sang QA, Schwartz MA, Hui L, Chung LWK, and Zhau HE. Targeting matrix metalloproteinases in human prostate cancer. *Ann. N.Y. Acad. Sci.* 878:538-540, 1999.
17. Shirakawa T, Gardner TA, Ko S-C, Bander N, Woo S, Gotoh A, Kamidono S, Chung LWK, and Kao C. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. *J. of Urol.* 162(3 Pt1):949-54, 1999.
18. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW. Osteopontin: possible role in prostate cancer progression. *Clinical Cancer Research* 5(8): 2271-7, 1999.
19. Chen ME, Lin SH, Chung LWK, and Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. *J of Biol. Chem.* 273:17618-17625, 1998.
20. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW, Frierson HF Jr. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. *Oncogene* 17(15):1979-82, 1998.
21. Gardner TA, Ko S-C, Kao C, Shirakawa T, Cheon J, Gotoh A, Wu TT, Sikes RA, Zhau HE, Cui Q, Balian G, and Chung LWK. Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. *Gene Ther. Mol. Biol.* 2:41-58, 1998.
22. Gotoh A, Ko S-C, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho L-J, Cleutjens CBJ, Trapman J, Graham FL, and Chung LWK. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. *J. of Urol.* 160:220-229, 1998.
23. Hwang ES, Kim J, Kim JS, Kao C, Ko S-C, Chung LWK, and Lee J-H. The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line *in vitro* and *in vivo*. *Int J. Gynecol. Cancer.* 8:27-36, 1998.

24. Jeng M-H, Kao C, Sivaraman L, Krnacik S, Chung LWK, Medina D, Conneely OM, and O'Malley BW. Reconstitution of estrogen-dependent transcriptional activation of an adenoviral target gene in select regions of the rat mammary gland. *Endocrinology*. 139:2916-2925, 1998.
25. Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LWK, von Eschenbach AC, and Pathak S. Telomeric DNA: Marker for human prostate cancer development? *The Prostate*. 36:264-271, 1998.
26. Ozen M, Navone NM, Multani AS, Troncso P, Logothetis CJ, Chung LWK, von Eschenbach AC, and Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. *Cancer Genet. Cytogenet.* 106:105-109, 1998.
27. Shen J, Zhau HYE, Hursting SD, and Chung LWK. Androgen regulation of the human pseudoautosomal gene *MIC2*, a potential marker for prostate cancer. *Molec. Carcinogenesis*. 23:13-19, 1998.
28. Shirakawa T, Ko S-C, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LWK, and Kao C. *In vivo* suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. *Cancer Gene Therapy*. 5(5): 274-280, 1998.
29. Sokoloff MH and Chung LWK. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. *Cancer & Metastasis Reviews*. 17(4):307-15, 1998.
30. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HYE, Balian G, and Chung LWK. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by PSA-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. *Int. J. Cancer*. 77:887-894, 1998.
31. Cheon J, Ko S-C, Gardner TA, Shirakawa T, Kao C, and Chung LWK. Chemogene therapy: Osteocalcin promoter based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. *Cancer Gene Therapy*. 4:359-365, 1997.
32. Chung LWK, Zhau HE and Wu TT. Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. *J. Cell Biochem (suppl)* 28/29:174-181, 1997.
33. Chung LWK, Kao C, Sikes RA, and Zhau HE. Human prostate cancer progression models and therapeutic intervention. *Acta Urol. Jpn.* 43:815-820, 1997.
34. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LWK, and Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. *Molec. Endocrino.* 11:1256-1265, 1997.
35. Gotoh A, Kamidono S, Chung LW. [Clinical application for gene therapy in prostate cancer][Japanese]. *Hinokika Kiyo—Acta Urologica Japonica* 43(11):829-33, 1997.
36. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, and Chung LWK. Cytotoxic effects of recombinant adenovirus p53 and cell-cycle regulator genes (p21^{WAF1/cip1} and p16^{INK4}) in human prostate cancers. *J. of Urol.* 158:636-641, 1997.
37. He D, Mu ZM, Le X, Hsieh JT, Pong RC, Chung LWK, and Chang KS. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. *Cancer Res.* 56:1868-1872, 1997.
38. Hyytinen E-R, Thalmann GN, Zhau HE, Karhu R, Kallioniemi O-P, Chung LWK, and Visakorpi T. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. *Brit. J. of Cancer*. 75:190-195, 1997.

39. Marengo SR, Sikes RA, Anezinis P, Chang S-M, and Chung LWK. Metastasis induced by overexpression of p185^{neu-T} after orthotopic injection into a prostatic epithelial cell line (NbE). *Molec. Carcinogenesis*. 19:165-175, 1997.
40. Ozen M, Multani AS, Kuniyasu H, Chung LWK, von Eschenbach AC, and Pathak S. Specific histologic and cytogenetic evidence for in vivo malignant transformation of murine host cells by three human prostate cancer cell lines. *Oncology Res*. 9:433-438, 1997.
41. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, and Chung LWK. Can cancer cells transform normal host cells into malignant cells? *Brit. J. of Cancer*. 76:1134-1138, 1997.
42. Bosland MC, Chung LWK, Greenberg NM, Ho S-M, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, and van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research: A minireview. *Urol. Oncol.* 2(4):99-128, 1997.
43. Zhau HE, Goodwin TJ, Chang S-M, Baker TL, and Chung LWK. Establishment of a 3-dimensional human prostate organoid co-culture under microgravity-simulated conditions: Evaluation of androgen-induced growth and PSA expression. *In Vitro Cell Dev. Biol.* 33:375-380, 1997.
44. Zhau HYE, Zhao L-S, Chen B-Q, and Kojima M. Interracial comparative study of prostate cancer in the U.S., China, and Japan. *J. of Cell. Biochem.* 28/29:182-186, 1997.
45. Chung, LW. Commentary on tumor suppressor gene, distal to BRCA-1, in prostate cancer. *J. Uro.* 155(2):430-1, 1996.
46. Chung LWK and Davies R. Prostate epithelial differentiation is dictated by its surrounding stroma. *Molec. Biol Reps.* 23:13-19, 1996.
47. Ko S-C, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, and Chung LWK. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. *Cancer Res.* 56:4614-4619, 1996.
48. Ko S-C, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, and Chung LWK. Molecular therapy with recombinant p53 adenovirus in an androgen-independent metastatic human prostate cancer model. *Human Gene Therapy*. 7:1683-1691, 1996.
49. Ozen M, Multani AS, Chang S-M, von Eschenbach AC, Chung LWK, and Pathak S. Establishment of an *in vitro* cell model system to study human prostate carcinogenesis: Involvement of chromosome 5 in early stages of neoplastic transformation. *Int. J. Oncology*. 8:883-888, 1996.
50. Thalmann GN, Sikes RA, Chang S-M, Johnston DA, von Eschenbach AC, and Chung LWK. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in LNCaP model of human prostate cancer. *J. Natl. Cancer Inst.* 88:794-801, 1996.
51. Zhau HYE, Chang S-M, Chen B-Q, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, and Chung LWK. Androgen-repressed phenotype in human prostate cancer. *Proc. Natl. Acad. Sci. USA*. 93:15152-15157, 1996.
52. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, and Chung LWK. Frequency and characterization of p53 mutations in clinically localized prostate cancer. *Urology*. 45:470-475, 1995.
53. Pistors LL, Troncoso P, Pollack A, Zhau HYE, Li W, von Eschenbach AC, and Chung LWK. *c-met* proto-oncogene expression in benign and malignant human prostate tissues. *J. of Urol.* 154:293-298, 1995.

54. Zhau HYE, Zhao L-S, Chung LWK, Chen B-Q, Troncoso P, Kao C, Kojima M, Symmans WF, Zheng N, Palmer JL, Moul JW, Davis R, Ye M-F, Xiao L-S, and Hall MC. Comparative studies of prostate cancers among U.S., Chinese, and Japanese patients: Characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. *Urologic Oncology*. 1(2):51-63, 1995.
55. Zhau HYE, Zhou J, Symmans WF, Chen B-Q, Chang SM, Sikes RA, and Chung LWK. Transfected *neu* oncogene induces human prostate cancer metastasis. *The Prostate*. 28:73-83, 1995.
56. Bandyk MG, Zhao L, Liang JC, Pisters LL, Troncoso P, Palmer JL, von Eschenbach AC, and Chung, LWK. Trisomy 7: A potential marker of human prostate cancer progression. *Genes, Chromo., and Cancer*. 9:19-27, 1994.
57. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, et al. The most promising surrogate endpoint for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. *J. of Cell. Biochem.-Suppl.* 19:283-9, 1994.
58. Freeman MF and Chung LWK. Alterations in gene expression, cytoskeletal organization, and behavioral properties in a novel cell line derived from an epithelial-mesenchymal interaction. *J. of Cell. Physiol.* 158(2):325-336, 1994.
59. Hall MC, Troncoso P, Pollack A, Zhau HYE, Zagars GK, Chung LWK, and von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. *Urology*. 44:869-875, 1994.
60. He XY, Sikes RA, Thomsen SL, and Chung LWK. Photodynamic therapy-induced programmed cell death in carcinoma cell lines. *Photochem. and Photobiol.* 59:468-473, 1994.
61. Marengo SR and Chung LWK. An orthotopic model for the study of growth factors in the ventral prostate of rat: effects of epidermal growth factor and basic fibroblast growth factor. *J. of Andrology*. 15(4):277-286, 1994.
62. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. *Seminars in Oncology*. 21(5):630-56, 1994.
63. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim E, Hopwood VL, Pathak S, von Eschenbach AE, and Chung LWK. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. *Cancer Res*. 54:2577-2581, 1994.
64. Wu HS, Hsieh JT, Gleave ME, Brown NM, Pathak S, and Chung LWK. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. *Int. J. of Cancer*. 57:406-412, 1994.
65. Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, and Chung LWK. Biomarkers associated with prostate cancer progression. *J. of Cell. Biochem. Suppl.* 19:208-216, 1994.
66. Zhau HYE, Hong S-J, and Chung LWK. A fetal rat urogenital sinus mesenchymal cell line (rUGM) accelerated growth and conferral of androgen-induced growth responsiveness to a human bladder cancer epithelial cell line in vivo. *Int. J. of Cancer*. 56:706-714, 1994.
67. Chung LW. Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. *Seminars in Cancer Biology* 4(3):183-192.
68. Gleave ME, Hsieh JT, Wu H-C, Hong S-J, Zhau HE, Guthrie PD, and Chung LWK. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. *Cancer Res*. 53(21):5300-5307, 1993.

69. Hoosein N, Logothetis CJ, and Chung LWK. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. *J. of Urol.* 149:1209-1213, 1993.
70. Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, and Chung LWK. Autoregulation of prostate-specific antigen and prostatic-specific antigen in human prostate cancer. *Cancer Res.* 53:2852-2857, 1993.
71. Chung LWK, Li W, Gleave M, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk M, Logothetis C, Rubin JS, and von Eschenbach AC. Human Prostate Cancer Model: Roles of Growth Factors and Extracellular Matrices. *J. of Cell. Biochem.* 16H:99-105, 1992.
72. Gleave ME, Hsieh JT, von Eschenbach AC, and Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional stromal-epithelial interaction in prostate carcinoma growth and metastasis. *J. of Urol.* 147:1151-1159, 1992.
73. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, and Chung LWK. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. *Cancer Res.* 52:1598-1605, 1992.
74. Hallas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Karioko K, Barnathan ES, and Boyd D. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell line. *Thromb. and Haemostasis.* 68:662-666, 1992.
75. Hsieh JT, Zhau HE, Wang XH, Liew CC, and Chung LWK. Regulation of basal- and luminal-specific cytokeratin expression in rat accessory sex organs: Evidence for a new class of androgen-repressed genes and insight into their pairwise control. *J. Biol. Chem.* 267:2303-2310, 1992.
76. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, and Campbell ML. Expression of the proto-oncogene Bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. *Cancer Res.* 52:6940-6944, 1992.
77. Sikes RA and Chung LWK. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. *Cancer Res.* 52:3174-3181, 1992.
78. Chung LW. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. *Cancer & Metastasis Reviews.* 10(3):263-74, 1991.
79. Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. *Cancer Surveys.* 11:91-121, 1991.
80. Freeman MR, Song Y, Carson D, Guthri PD, and Chung LWK. Extracellular matrix and androgen receptor expression associated with spontaneous transformation of rat prostate fibroblasts. *Cancer Res.* 51:1910-1916, 1991.
81. Gleave ME, Hsieh JT, Gao C, Chung LWK, and von Eschenbach AC. Acceleration of human prostate cancer growth *in vivo* by prostate and bone fibroblasts. *Cancer Res.* 51:3753-3761, 1991.
82. Hoosein NM, Boyd DD, Holas WJ, Mazar A, Henkin J, and Chung LWK. Correlation of levels of urokinase and its receptor with the invasiveness of human prostatic carcinoma cell lines. *Cancer Communications.* 3(8):255-264, 1991.
83. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HYE, von Eschenbach AC, and Chung LWK. Fibroblast-mediated acceleration of human epithelial tumor growth *in vivo*. *Proc. Natl. Acad. Sci.* 87(1):75-79, 1990.

84. Chung LWK, Zhau HE, and Ro JY. Morphologic and biochemical alterations in rat prostatic tumors induced by fetal urogenital sinus mesenchyme. *The Prostate*. 17:165-174, 1990.
85. Guthrie PD, Freeman MR, Liao ST, Chung LW. Regulation of gene expression in rat prostate by androgen and beta-adrenergic receptor pathways. *Molecular Endocrinology*. 4(9):1343-53, 1990.
86. Guthrie PD, Freeman MR, Shut-sung L, and Chung LWK. Evidence for the involvement of androgen and β -adrenergic receptor pathways in the functional differentiation and the expression of prostatic binding protein in rat ventral prostate. *Molecular Endocrinology*. 4:1343-1353, 1990.
87. Sikes RA, Thomsen S, Petrow V, Neubauer BL, and Chung LWK. Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration. *Biol. of Reprod.* 43(3):353-362, 1990.
88. Chang S-M and Chung LWK. Interaction between prostatic fibroblast and epithelial cells in culture: Role of Androgen. *Endocrinology*. 125 (5):2719-2727, 1989.
89. Chung LWK, Chang S-M, Bell C, Zhau HE, Ro JY, and von Eschenbach AC. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. *Int. J. Cancer*. 43:1179-1187, 1989.
90. Freeman MR, Washecka R, and Chung LWK. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) mRNAs in human renal cancers. *Cancer Res.* 49:6221-6225, 1989.
91. Chung LWK and Auble K. Characterization of fetal urogenital sinus-induced prostatic hyperplasia in the mouse: Time course, hormonal requirement, age dependency and responsiveness of various adult organs to growth induction by fetal urogenital sinus tissues. *Biol. of Reprod.* 39:50-57, 1988.
92. Chung LWK, Chang S-M, Bell C, Zhau H, Ro JY, and von Eschenbach AC. Prostatic carcinogenesis evoked by cellular interaction. *Env. Health Perspectives*. 77:23-28, 1988.
93. Simpson VJ, Chung LWK, and Runner MN. Coordinated maternal imprinting and paternal genotype determine the ultimate level of hepatic cytochromes P-450 and associated monooxygenase activities. *Drug Metabolism and Disposition*. 16:576-581, 1988.
94. Anderson NG, Miller GJ, Chung LW. Assessment of the effect of androgen and estrogen on the development of prostatic adenocarcinoma and urinary bladder calculi in Nb rats. *Progress in Clinical & Biological Research*. 239:283-95, 1987.
95. Thompson TC, Zhau HY, Chung LW. Catecholamines are involved in the growth and expression of prostatic binding protein by rat ventral prostatic tissues. *Progress in Clinical & Biological Research*. 239:239-48, 1987.
96. Thompson TC and Chung LWK. Regulation of growth and expression of prostatic binding protein in chimeric prostate gland. *Endocrinology*. 118:2437-2444, 1986.
97. Thompson TC, Cunha GR, Shannon JM, and Chung LWK. Androgen-induced biochemical responses in tissues lacking epithelial androgen receptors: Characterization of androgen receptors in the mesenchyme of urogenital sinus-derived tissues. *J. Steroid Biochem.* 25:627-634, 1986.
98. Chung LW, Auble K. An experimental model for mouse prostatic hyperplasia: characterization of hormonal, age and tissue specificities. *Proceedings of the Western Pharmacology Society*. 28:35-9, 1985.
99. Miller GJ, Runner MN, and Chung LWK. Tissue interactions and prostatic growth. II. Morphological and biochemical characterization of adult mouse prostatic hyperplasia induced by fetal urogenital sinus implants. *The Prostate*. 6:241-253, 1985.

100. Neubauer BL, Anderson NG, Cunha GR, Towell JF, and Chung LWK. Androgen metabolism in tissue recombinants composed of adult urinary bladder epithelium and urogenital sinus mesenchyme. *J. Steroid Biochem.* 23:95-102, 1985.
101. Chung LWK, Matsuura J, and Runner MN. Tissue interactions and prostatic growth. I. Induction of adult mouse prostate hyperplasia by fetal urogenital sinus implants. *Biol. of Reprod.* 31:155-163, 1984.
102. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. Tissue interactions and prostatic growth: a new mouse model for prostatic hyperplasia. *Annals of the New York Academy of Sciences.* 438:394-404, 1984.
103. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. *Progress in Clinical & Biological Research.* 145:291-306, 1984.
104. Thompson TC, Chung LW. Evidence for a soluble fetal urogenital sinus-derived growth factor(s). *Annals of the New York Academy of Sciences.* 438:582-5, 1984.
105. Thompson TC and Chung LWK. Extraction of nuclear androgen receptors by sodium molybdate from normal rat prostates and prostatic tumors. *Cancer Res.* 44:1019-1026, 1984.
106. Chung LWK and Breitweiser K. Comparison of soluble protein kinases from normal rat prostates and prostatic Dunning tumors. *Cancer Res.* 83:3297-3304, 1983.
107. Chung LWK and Cunha GR. Stromal-epithelial interactions. II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. *The Prostate.* 4:503-511, 1983.
108. Cunha GR, Chung LW, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. *Recent Progress in Hormone Research.* 39:559-98, 1983.
109. Neubauer BL, Chung LWK, McCormick KA, Taguchi O, Thompson TC, and Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. *J. Cell. Biol.* 96:1671-1677, 1983.
110. Chao HY and Chung LWK. Neonatal imprinting and hepatic cytochrome P-450. Immunochemical evidence for the presence of sex-dependent and neonatally imprinted form(s) of hepatic cytochrome P-450. *Molecular Pharmacol.* 21:744-752, 1982.
111. Chung LW, Matsuura J, Thompson TC, Chao RC. A new approach to regulation of prostatic growth: interactions between embryonic urogenital sinuses and adult prostate in situ. *Proceedings of the Western Pharmacology Society.* 25:141-5, 1982.
112. Simpson VJ, Chung LW. Programming of rat hepatic arylhydrocarbon hydroxylase activity during late neonatal period. *Proceedings of the Western Pharmacology Society.* 25:257-61, 1982.
113. Chao H, Chung LW. Isolation and characterization of a sex dependent and neonatally imprinted form(s) of hepatic cytochrome P-450. *Proceedings of the Western Pharmacology Society.* 24:295-8, 1981.
114. Chung LWK, Colvin M, and Chao H. Neonatal imprinting and hepatic cytochrome P-450. II. Partial purification of a sex-dependent and neonatally imprinted form of hepatic cytochrome P-450. *J. Supramol. Structure and Cell Biochem.* 15:193-204, 1981.
115. Chung LW, Thompson TC, Breitweiser K. Sensitive biochemical methods to distinguish hormone dependent and independent Dunning tumors of prostatic origin. *Proceedings of the Western Pharmacology Society.* 24:305-10, 1981.

116. Cunha GR and Chung LWK. Stromal-epithelial interactions. I. Introduction of prostatic phenotype of urothelium of testicular feminized (Tfm/y) mice. *J. Steroid Biochem.* 14:1317-1321, 1981.
117. Cunha GR, Shannon JM, Neubauer BL, Sawyer LM, Fujii H, Taguchi O, and Chung LWK. Mesenchymal-epithelial interactions in sexual differentiation. *Human Genetics.* 58:68-71, 1981.
118. Neubauer BL, Anderson NG, Cunha GR, Towell JF, Chung LW. A new isocratic HPLC system for the measurement of in vitro testosterone metabolism in tissue recombinants composed of adult mouse urinary bladder epithelium and urogenital sinus mesenchyme. *Proceedings of the Western Pharmacology Society.* 24:289-93, 1981.
119. Chung LWK and Chao H. Neonatal imprinting and hepatic cytochrome P-450. I. Comparison of testosterone hydroxylation between neonatally imprinted and non-imprinted rats. *Molecular Pharmacol.* 18:543-549, 1980.
120. Chung LWK and MacFadden DK. Biochemical and morphological modification of rat accessory sex organs by postnatal steroid treatment. *Invest. Urology.* 7:337-342, 1980.
121. Cunha GR, Chung LWK, Shannon JM, and Reese BA. Stromal-epithelial interactions in sex differentiation. *Biol. of Reprod.* 22:19-42, 1980.
122. French T, Atkinson N, Peterson D, and Chung LWK. Differential induction of ethanol and drug metabolism by 3-methylcholanthrene in the "LS" and "SS" mice. *J. Pharmacol. Exp. Therap.* 209:404-410, 1979.
123. Chung LWK and Coffey DS. Androgen glucuronide. II. Differences in its formation by human normal and benign hyperplastic prostates. *Invest. Urology.* 15:385-389, 1978.
124. Chung LWK and Coffey DS. Androgen glucuronide. I. Direct formation in rat accessory sex organs. *Steroids.* 30:223-243, 1977.
125. Chung LWK. Characteristics of neonatal androgen-induced imprinting of hepatic microsomal monooxygenases in rats. *Biochem. Pharmacol.* 26:1979-1984, 1977.
126. Chung LWK, Raymond G, and Fox S. Role of neonatal androgen in the development of hepatic microsomal drug metabolizing enzymes. *J. Pharmacol. Exp. Therap.* 193:621-630, 1975.
127. Chung LWK and Raymond G. Differences among rat sex accessory glands in their neonatal androgen-dependency. *Endocrinology.* 97:145-153, 1975.
128. Chung LWK and Coffey DS. Biochemical characterization of prostatic nuclei. II. Relationship between DNA synthesis and protein synthesis. *Biochem. Biophys. Acta.* 247:584-596, 1971.
129. Chung LWK and Coffey DS. Biochemical characterization of prostatic nuclei. I. Androgen-induced changes of nuclear proteins. *Biochem. Biophys. Acta.* 247:570-583, 1971.
130. Chung LWK and Gabourel JD. Adrenal steroid release by vinblastine and its contribution to vinblastine effect on rat thymus. *Biochem. Pharmacol.* 10:1759, 1971.

Manuscripts Submitted

1. Koeneman KS, Gardner TA, Yang L, Gillenwater JY, Chung LWK, and Macik BG. Elevated aPTT during administration of first generation adenoviral vectors for gene therapy: Identification of lupus anticoagulants (LAC). *Human Gene Therapy.* Submitted, 2001.

2. Cinar B and Chung LWK. Introduction of an androgen receptor to a human prostate cancer cell line restores androgen induced cell proliferation and target gene. *Cancer Research*. Submitted, 2001.

Published and Accepted Invited Journal Articles

1. Chung LWK. Commentary on tumor suppressor gene, distal to BRCA-1, in prostate cancer. *J. of Urol.* 155:430-431, 1996.
2. Chung LWK. The role of stromal-epithelial interaction in normal and malignant growth. *Cancer Surveys*. 23:33-42, 1995.
3. Gleave ME and Chung LWK. Stromal-epithelial interaction affecting prostatic tumour growth and humoral responsiveness. *Endocrine-Related Cancer*. 2:243-265, 1995.
4. Chung LWK. Comments on "Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors" and "Prostate-specific antigen in milk of lactating women". In: *Breast Diseases - A Yearbook Quarterly*. 6:272, 1995.
5. Chung LWK, Gao C, Li W, and Zhau HE. Stromal-epithelial interaction: Implications for prostate tumorigenesis. *Cancer Bulletin*. 45:430-435, 1993.
6. Chung LWK. Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. *Seminars in Cancer Biol.* 4:183-192, 1993.
7. Chung LWK. Prostatic duct biology. *Perspectives: Contemporary issues in managing prostatic disease*. 3(1):5-6, 1993.
8. Marengo SR and Chung LWK. Growth factor matrix induces prostatic growth *in situ*. *AUA Today*. 6(3):1 and 6, 1993.
9. Anderson NG, Miller GJ, and Chung LWK. Assessment of the effect of androgen and estrogen on the development of prostatic adenocarcinoma and urinary bladder calculi in Nb rats. *Prog. in Clin. and Biol. Res.* 239:283-296, 1987.
10. Thompson TC, Zhau H, and Chung LWK. Catecholamines are involved in the growth and expression of prostatic binding protein by rat ventral prostatic tissues. *Prog. in Clin. and Biol. Res.* 239:239-250, 1987.
11. Thompson TC and Chung LWK. Evidence of soluble fetal urogenital sinus-derived growth factor(s). *Ann. N.Y. Acad. Sci.* 438:582-585, 1985.
12. Chung LWK. Tissue interactions and prostatic growth. *Ann. N.Y. Acad. Sci.* 438:394-404, 1985.
13. Cunha GR, Chung LWK, Shannon JM, Taguchi O, and Fujii H. Hormone-induced morphogenesis and growth: Role of mesenchymal-epithelial interactions. *Recent Progress in Hormone Res.* 39:559-598, 1983.
14. Chung LWK, Matsuura J, Thompson TC, and Chao RCF. A new approach to regulation of prostatic growth: Interactions between embryonic urogenital sinuses and adult prostate *in situ*. *Proc. West. Pharmacol. Soc.* 25:141-145, 1982.
15. Cunha GR, Shannon JM, Taguchi O, Fujii H, and Chung LWK. Mesenchymal epithelial interactions in hormone-induced development. *J. Am. Sci.* 55(suppl. II):14-31, 1982.
16. Chao H and Chung LWK. Isolation and characterization of a sex-dependent and neonatally imprinted form(s) of hepatic cytochrome P-450. *Proc. West. Pharmacol. Soc.* 24:295-298, 1981.
17. Chung LWK, Thompson T C, and Breitweiser K. Sensitive biochemical methods to distinguish hormone-dependent and independent Dunning tumors of prostatic origin. *Proc. West. Pharmacol. Soc.* 24:305-310, 1981.

18. Neubauer BL, Anderson NG, Cunha GR, Towell JF, and Chung LWK. A new isocratic HPLC system for the measurement of *in vitro* testosterone metabolism in tissue recombinants composed of adult urinary bladder epithelium and urogenital sinus mesenchyme. *Proc. West. Pharmacol. Soc.* 24:289-293, 1981.

Book Chapters

1. Chung LWK and Zhau HYE. Stromal-epithelial interaction: From bench to bedside. In: *Prostate Cancer: Biology, Genetics, and the New Therapeutics*. Eds. LWK Chung, WB Isaacs, and JW Simons. Humana Press, Inc., Totowa, NJ. December, 2000.
2. Hsieh J-T, Dinney CPN, and Chung LWK. The potential role of gene therapy in the treatment of bladder cancer. *Urologic Clinics of North America*. 27(1):103-113, 2000.
3. Gleave M, Bandyk M, and Chung L. Prostate Cancer. In: *Advances in Oncobiology*. Eds: G Heppner and EE Bittar. Jai Press, Inc., London, 1:257-292, 1996.
4. Thalmann GN, Anezinis P, Devoll R, Farach-Carson C, and Chung LWK. Experimental approaches to skeletal metastasis of human prostate cancer. In: *Principles and Practice of Genitourinary Oncology*. Lippincott and Raven, 1996.
5. Chung LWK and Zhau HE. The role of stromal-epithelial interaction in the normal and abnormal growth of the prostate. In: *Basic Research in Urologic Oncology*. Eds: L Luciani, FMJ Debruyne, and JA Schalken, pp. 16-27, 1996.
6. Freeman MR, Gleave ME, and Chung LWK. Stromal-epithelial interactions: Molecular aspects and relevance to benign prostatic hyperplasia. In: *Textbook of Benign Prostatic Hyperplasia*. Eds: R Kirby, JD McConnell, JM Fitzpatrick, CG Roehrborn, and P Boyle. ISIS Medical Media, Oxford, pp. 57-74, 1996.
7. Chung LWK, Hong S-J, Gleave ME, Zhau HYE. Cellular communication mediated by soluble growth factors are responsible for determining androgen responsiveness of benign and malignant growth of the prostate gland. In: *Basic Research and Therapeutics Aspects of Benign Prostatic Hyperplasia and Prostate Cancer*. Eds: A Akdas and LN Turkeri, 1995.
8. Chung LWK and Anezinis P. The role of stromal epithelial interactions in the normal and abnormal growth of the prostate. In: *Basic Research in Urological Oncology*. Eds: S Karger and AG Basel, 1995.
9. Chung LWK, Isaacs B, and Trapman J. Genes, matrices and cytokines. In: *Tumor Biology*. Ed: E.J. Freireich, 1995.
10. Chung LWK. Comments on "Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors" and "Prostate-specific antigen in milk of lactating women." In: *Breast Diseases - A Yearbook Quarterly*. 6:272, 1995.
11. Sikes RA, Kao C, and Chung LWK. Autocrine and paracrine mediators for prostate growth and cancer progression. In: *Advances in Urology*. Ed: EJ McGuire, Blackwell Scientific Publications, 8:21-60, 1995.
12. Chung LWK, Bandyk MG, and Gleave ME. Prostate neoplasm. In: *Principles of Medical Biology*. Ed: ED Bittar, JAI Press, 1995.
13. Scher HI and Chung LWK. Bone metastases: Improving the therapeutic Index. In: *Seminars in Oncology on Prostate Cancer*. 21:630-656, 1994.
14. Zhau HYE, Sikes RA, and Chung LWK. The c-erb B2 oncogene in human prostate cancer growth and progression. In: *Protooncogenes and Growth Factors in Steroid Hormone-Induced Growth and Differentiation*. Eds: SA Khan and GM Stancel, CRC Press, Boca Raton, pp. 207-220, 1994.

15. He XY, Sikes RA, Thompson S, Chung LWK, and Jacques SL. Photodynamic therapy-induced programmed cell death in carcinoma cell lines. In: *Proceedings of SPIE*. 1993.
16. Chung LWK. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. In: *Cancer and Metastasis Review*. 10:263-274, 1991.
17. Chung LWK, Gleave ME, Hsieh JT, and Zhau HE. Bidirectional mesenchymal-epithelial interaction affecting prostate cancer growth and hormonal responsiveness. In: *Cancer Survey*. 11: 91-121, 1991.
18. Freeman MF, Song Y, Carson D, Guthrie PD, and Chung LWK. Effect of transformation on rat prostatic fibroblasts: alterations in extracellular matrix and cytoskeleton gene expression with retention of androgen responsiveness and androgen receptor expression. In: *Molecular and Cellular Biology of Prostate Cancer*. Proceedings of a Symposium on "Molecular and Cellular Biology of Prostate Cancer". Eds: JP Karr, DS Coffey, RG Smith, and DJ Tindall, Plenum Press, New York, pp. 273-274, 1991.
19. Chung LWK, Hong SJ, Zhau HE, Camps JL, Chang S-M, Freeman MF, and Gao C. Fibroblast-mediated human epithelial tumor growth and hormonal responsiveness *in vivo*. In: *Molecular and Cellular Biology of Prostate Cancer*. Proceedings of a Symposium on "Molecular and Cellular Biology of Prostate Cancer". Eds: JP Karr, DS Coffey, RG Smith, and DJ Tindall, Plenum Press, New York, pp. 91-102, 1991.
20. Chung LWK, Camps JL, and von Eschenbach AC. Cancer Biology. In: *Scientific Foundations of Urology, 3rd Edition*. Eds: GD Chisholm and W Fair, Year Book Medical Publishers, pp. 459-474, 1990.
21. Chung LWK. Isoenzymes in Prostate Cancer. In: *Urologic Oncology*. Matrinus Nijhoff Publishers, pp. 1-3, 1986.
22. Chung LWK, Thompson TC, Chao H, Bell C, and Ruth JA. Catecholamines are involved in stromal epithelial interactions in rat ventral prostate gland. In: *The 2nd NIADDK Symposium on the Study of Benign Prostatic Hyperplasia*. May 16-19, pp. 27-33, 1985.
23. Chung LWK, Thompson TC, and Rocco AK. Role of androgen receptors in stromal-epithelial interactions in prostate cancer. In: *Urologic Oncology*. Matrinus Nijhoff Publishers, pp. 27-38, 1984.
24. Cunha GR, Taguchi O, Shannon JM, Chung LWK, and Bigsby RM. Mesenchymal role in hormone-induced epithelial development. In: *Sexual Differentiation: Basic and Clinical Aspects*. Eds: M Serio et al. Raven Press, New York, 1984.
25. Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ, and Runner MN. A new mouse model for prostatic hyperplasia: Induction of adult prostatic overgrowth by fetal urogenital sinus implants. In: *New Approaches to the Study of Benign Prostatic Hyperplasia*. Alan R. Liss, Inc., pp. 291-306, 1984.
26. Chung LWK, Anderson NG, Neubauer BL, Cunha GR, Thompson TC, and Rocco AK. Tissue interactions in prostate development: Roles of sex steroids. In: *Prostatic Cells: Structure and Function*. Alan R. Liss, Inc., pp. 177-203, 1981.
27. Neims AH, Warner M, Chung LWK, Yang G, and East S. Relative deficiency of the elimination of hexachlorophene by neonatal rodents. In: *Basic and Therapeutic Aspects of Perinatal Pharmacology*. Raven Press, pp. 177-190, 1975.
28. Neims AH, Chung LWK, Weimar W, and Hales B. Perinatal toxicology: The question of delayed and residual effects. In: *First International Congress on Alcohol and Drug Addition*. University Press, Toronto, pp. 15-33, 1975.
29. Carter MF, Chung LWK, and Coffey DS. The temporal requirements for androgens during the cell cycle of the prostate gland. In: *Festschrift. Urological Research*. Eds. L. R. King and G. P. Murphy. Plenum Publishers, New York, pp. 27-35, 1972.

Other Publications:

Available upon request